WO2024013258A1 - Production of cysteine or cystine from serine in fermentation medium - Google Patents
Production of cysteine or cystine from serine in fermentation medium Download PDFInfo
- Publication number
- WO2024013258A1 WO2024013258A1 PCT/EP2023/069370 EP2023069370W WO2024013258A1 WO 2024013258 A1 WO2024013258 A1 WO 2024013258A1 EP 2023069370 W EP2023069370 W EP 2023069370W WO 2024013258 A1 WO2024013258 A1 WO 2024013258A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- phosphate
- identity
- serine
- comprised
- Prior art date
Links
- 238000000855 fermentation Methods 0.000 title claims abstract description 130
- 230000004151 fermentation Effects 0.000 title claims abstract description 130
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 title claims abstract description 96
- 229960003067 cystine Drugs 0.000 title claims abstract description 73
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 title claims abstract description 66
- 235000018417 cysteine Nutrition 0.000 title claims abstract description 66
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 32
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 title claims description 119
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 title abstract 5
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 claims abstract description 102
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 claims abstract description 102
- 229960001327 pyridoxal phosphate Drugs 0.000 claims abstract description 102
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 claims abstract description 93
- 102000004190 Enzymes Human genes 0.000 claims abstract description 65
- 108090000790 Enzymes Proteins 0.000 claims abstract description 65
- 230000001419 dependent effect Effects 0.000 claims abstract description 42
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract description 34
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 34
- 239000011593 sulfur Substances 0.000 claims abstract description 34
- 229960001153 serine Drugs 0.000 claims description 161
- 229960002433 cysteine Drugs 0.000 claims description 98
- 108090000623 proteins and genes Proteins 0.000 claims description 92
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims description 68
- 238000000034 method Methods 0.000 claims description 67
- 108010075344 Tryptophan synthase Proteins 0.000 claims description 45
- 238000006243 chemical reaction Methods 0.000 claims description 44
- LXJXRIRHZLFYRP-VKHMYHEASA-L (R)-2-Hydroxy-3-(phosphonooxy)-propanal Natural products O=C[C@H](O)COP([O-])([O-])=O LXJXRIRHZLFYRP-VKHMYHEASA-L 0.000 claims description 42
- LXJXRIRHZLFYRP-VKHMYHEASA-N D-glyceraldehyde 3-phosphate Chemical compound O=C[C@H](O)COP(O)(O)=O LXJXRIRHZLFYRP-VKHMYHEASA-N 0.000 claims description 42
- GNGACRATGGDKBX-UHFFFAOYSA-N dihydroxyacetone phosphate Chemical compound OCC(=O)COP(O)(O)=O GNGACRATGGDKBX-UHFFFAOYSA-N 0.000 claims description 38
- 239000004201 L-cysteine Substances 0.000 claims description 37
- 235000013878 L-cysteine Nutrition 0.000 claims description 37
- 150000001875 compounds Chemical class 0.000 claims description 33
- 239000000758 substrate Substances 0.000 claims description 30
- 241000894006 Bacteria Species 0.000 claims description 29
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 27
- LJQLQCAXBUHEAZ-UWTATZPHSA-N 3-phospho-D-glyceroyl dihydrogen phosphate Chemical compound OP(=O)(O)OC[C@@H](O)C(=O)OP(O)(O)=O LJQLQCAXBUHEAZ-UWTATZPHSA-N 0.000 claims description 26
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 claims description 25
- 102100037579 D-3-phosphoglycerate dehydrogenase Human genes 0.000 claims description 24
- 108010038555 Phosphoglycerate dehydrogenase Proteins 0.000 claims description 24
- -1 ammonium ions Chemical class 0.000 claims description 23
- 230000037361 pathway Effects 0.000 claims description 23
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 claims description 22
- 101150073818 gap gene Proteins 0.000 claims description 22
- 238000004113 cell culture Methods 0.000 claims description 21
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 claims description 20
- 102100021762 Phosphoserine phosphatase Human genes 0.000 claims description 20
- 229950006137 dexfosfoserine Drugs 0.000 claims description 20
- 102000030592 phosphoserine aminotransferase Human genes 0.000 claims description 20
- 108010088694 phosphoserine aminotransferase Proteins 0.000 claims description 20
- 108010076573 phosphoserine phosphatase Proteins 0.000 claims description 20
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 claims description 19
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 claims description 19
- 102000030595 Glucokinase Human genes 0.000 claims description 17
- 108010021582 Glucokinase Proteins 0.000 claims description 17
- 102000005731 Glucose-6-phosphate isomerase Human genes 0.000 claims description 17
- 108010070600 Glucose-6-phosphate isomerase Proteins 0.000 claims description 17
- 101710137787 Glyceraldehyde-3-phosphate dehydrogenase A Proteins 0.000 claims description 17
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 claims description 17
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 claims description 17
- 102000005924 Triose-Phosphate Isomerase Human genes 0.000 claims description 17
- 108700015934 Triose-phosphate isomerases Proteins 0.000 claims description 17
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 claims description 17
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 claims description 17
- 101150100557 pfkB gene Proteins 0.000 claims description 17
- 241000588724 Escherichia coli Species 0.000 claims description 16
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 16
- 108010022678 Phosphofructokinase-2 Proteins 0.000 claims description 16
- 102000012434 Phosphofructokinase-2 Human genes 0.000 claims description 16
- 239000008103 glucose Substances 0.000 claims description 15
- 230000000865 phosphorylative effect Effects 0.000 claims description 15
- 239000002028 Biomass Substances 0.000 claims description 14
- GSXOAOHZAIYLCY-UHFFFAOYSA-N D-F6P Natural products OCC(=O)C(O)C(O)C(O)COP(O)(O)=O GSXOAOHZAIYLCY-UHFFFAOYSA-N 0.000 claims description 14
- 150000001413 amino acids Chemical class 0.000 claims description 14
- BGWGXPAPYGQALX-ARQDHWQXSA-N beta-D-fructofuranose 6-phosphate Chemical compound OC[C@@]1(O)O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O BGWGXPAPYGQALX-ARQDHWQXSA-N 0.000 claims description 14
- UUQMNUMQCIQDMZ-UHFFFAOYSA-N betahistine Chemical compound CNCCC1=CC=CC=N1 UUQMNUMQCIQDMZ-UHFFFAOYSA-N 0.000 claims description 14
- 238000012258 culturing Methods 0.000 claims description 14
- 239000000047 product Substances 0.000 claims description 14
- 101150003830 serC gene Proteins 0.000 claims description 14
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 claims description 13
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 claims description 13
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 12
- 229920001184 polypeptide Polymers 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 12
- 101100508888 Bacillus subtilis (strain 168) iolJ gene Proteins 0.000 claims description 11
- 101100280051 Brucella abortus biovar 1 (strain 9-941) eryH gene Proteins 0.000 claims description 11
- 239000004158 L-cystine Substances 0.000 claims description 11
- 235000019393 L-cystine Nutrition 0.000 claims description 11
- 101100235161 Mycolicibacterium smegmatis (strain ATCC 700084 / mc(2)155) lerI gene Proteins 0.000 claims description 11
- 101150031187 fba gene Proteins 0.000 claims description 11
- 101150108901 fbaA gene Proteins 0.000 claims description 11
- 101150050376 fbaB gene Proteins 0.000 claims description 11
- 101150111583 fda gene Proteins 0.000 claims description 11
- HYHCSLBZRBJJCH-UHFFFAOYSA-M sodium hydrosulfide Chemical compound [Na+].[SH-] HYHCSLBZRBJJCH-UHFFFAOYSA-M 0.000 claims description 11
- 101150080369 tpiA gene Proteins 0.000 claims description 11
- 101710107802 Fructose-bisphosphate aldolase class 1 Proteins 0.000 claims description 10
- 101710107796 Fructose-bisphosphate aldolase class 2 Proteins 0.000 claims description 10
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 10
- 101100261636 Methanothermobacter marburgensis (strain ATCC BAA-927 / DSM 2133 / JCM 14651 / NBRC 100331 / OCM 82 / Marburg) trpB2 gene Proteins 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 10
- 101150019416 trpA gene Proteins 0.000 claims description 10
- 101150081616 trpB gene Proteins 0.000 claims description 10
- 101150111232 trpB-1 gene Proteins 0.000 claims description 10
- 229940024606 amino acid Drugs 0.000 claims description 9
- 235000001014 amino acid Nutrition 0.000 claims description 9
- 229910000037 hydrogen sulfide Inorganic materials 0.000 claims description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 claims description 8
- 229910019142 PO4 Inorganic materials 0.000 claims description 8
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 8
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 8
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 8
- RNBGYGVWRKECFJ-UHFFFAOYSA-N fructose-1,6-phosphate Natural products OC1C(O)C(O)(COP(O)(O)=O)OC1COP(O)(O)=O RNBGYGVWRKECFJ-UHFFFAOYSA-N 0.000 claims description 8
- 230000000813 microbial effect Effects 0.000 claims description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 8
- 239000010452 phosphate Substances 0.000 claims description 8
- 239000002243 precursor Substances 0.000 claims description 8
- 235000018102 proteins Nutrition 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- XPYBSIWDXQFNMH-UHFFFAOYSA-N D-fructose 1,6-bisphosphate Natural products OP(=O)(O)OCC(O)C(O)C(O)C(=O)COP(O)(O)=O XPYBSIWDXQFNMH-UHFFFAOYSA-N 0.000 claims description 7
- RNBGYGVWRKECFJ-ARQDHWQXSA-N beta-D-fructofuranose 1,6-bisphosphate Chemical compound O[C@H]1[C@H](O)[C@@](O)(COP(O)(O)=O)O[C@@H]1COP(O)(O)=O RNBGYGVWRKECFJ-ARQDHWQXSA-N 0.000 claims description 7
- 230000030609 dephosphorylation Effects 0.000 claims description 7
- 238000006209 dephosphorylation reaction Methods 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 230000003647 oxidation Effects 0.000 claims description 7
- 238000007254 oxidation reaction Methods 0.000 claims description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- 241000588722 Escherichia Species 0.000 claims description 6
- 230000006696 biosynthetic metabolic pathway Effects 0.000 claims description 6
- 239000004202 carbamide Substances 0.000 claims description 6
- 150000001720 carbohydrates Chemical class 0.000 claims description 6
- 235000014633 carbohydrates Nutrition 0.000 claims description 6
- 239000011573 trace mineral Substances 0.000 claims description 6
- 235000013619 trace mineral Nutrition 0.000 claims description 6
- 239000004475 Arginine Substances 0.000 claims description 5
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 5
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 5
- 235000004279 alanine Nutrition 0.000 claims description 5
- 150000003868 ammonium compounds Chemical class 0.000 claims description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 229910052802 copper Inorganic materials 0.000 claims description 5
- 150000002016 disaccharides Chemical class 0.000 claims description 5
- 229910052742 iron Inorganic materials 0.000 claims description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 5
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 5
- 229910052748 manganese Inorganic materials 0.000 claims description 5
- 239000002207 metabolite Substances 0.000 claims description 5
- 229910052750 molybdenum Inorganic materials 0.000 claims description 5
- 150000002772 monosaccharides Chemical class 0.000 claims description 5
- 230000035772 mutation Effects 0.000 claims description 5
- 150000002823 nitrates Chemical class 0.000 claims description 5
- 230000003287 optical effect Effects 0.000 claims description 5
- 230000001590 oxidative effect Effects 0.000 claims description 5
- 229910000160 potassium phosphate Inorganic materials 0.000 claims description 5
- 235000011009 potassium phosphates Nutrition 0.000 claims description 5
- 238000000926 separation method Methods 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 229910052725 zinc Inorganic materials 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- JJIHLJJYMXLCOY-BYPYZUCNSA-N N-acetyl-L-serine Chemical compound CC(=O)N[C@@H](CO)C(O)=O JJIHLJJYMXLCOY-BYPYZUCNSA-N 0.000 claims description 4
- 230000002238 attenuated effect Effects 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 230000026731 phosphorylation Effects 0.000 claims description 4
- 238000006366 phosphorylation reaction Methods 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 4
- CKLJMWTZIZZHCS-UHFFFAOYSA-N Aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 3
- 150000007513 acids Chemical class 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 3
- 239000003463 adsorbent Substances 0.000 claims description 3
- 150000007514 bases Chemical class 0.000 claims description 3
- 239000003925 fat Substances 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 235000013379 molasses Nutrition 0.000 claims description 3
- 239000003921 oil Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 108090000023 Carbon-oxygen lyases Proteins 0.000 claims description 2
- 102000003732 Carbon-oxygen lyases Human genes 0.000 claims description 2
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims description 2
- 108090001042 Hydro-Lyases Proteins 0.000 claims description 2
- 102000004867 Hydro-Lyases Human genes 0.000 claims description 2
- 102000004317 Lyases Human genes 0.000 claims description 2
- 108090000856 Lyases Proteins 0.000 claims description 2
- 102220509535 SMAD5 antisense gene protein 1_D47S_mutation Human genes 0.000 claims description 2
- 230000002378 acidificating effect Effects 0.000 claims description 2
- 238000013019 agitation Methods 0.000 claims description 2
- 238000002425 crystallisation Methods 0.000 claims description 2
- 230000008025 crystallization Effects 0.000 claims description 2
- 238000001704 evaporation Methods 0.000 claims description 2
- 230000005484 gravity Effects 0.000 claims description 2
- 239000000543 intermediate Substances 0.000 claims description 2
- 238000004255 ion exchange chromatography Methods 0.000 claims description 2
- 238000002955 isolation Methods 0.000 claims description 2
- 238000006317 isomerization reaction Methods 0.000 claims description 2
- 239000007791 liquid phase Substances 0.000 claims description 2
- 230000010627 oxidative phosphorylation Effects 0.000 claims description 2
- 230000001376 precipitating effect Effects 0.000 claims description 2
- 238000011084 recovery Methods 0.000 claims description 2
- 229920005989 resin Polymers 0.000 claims description 2
- 239000011347 resin Substances 0.000 claims description 2
- 238000004366 reverse phase liquid chromatography Methods 0.000 claims description 2
- 102200146932 rs34936594 Human genes 0.000 claims description 2
- 239000001394 sodium malate Substances 0.000 claims description 2
- LFLUCDOSQPJJBE-UHFFFAOYSA-N 3-phosphonooxypyruvic acid Chemical compound OC(=O)C(=O)COP(O)(O)=O LFLUCDOSQPJJBE-UHFFFAOYSA-N 0.000 claims 8
- 125000000415 L-cysteinyl group Chemical group O=C([*])[C@@](N([H])[H])([H])C([H])([H])S[H] 0.000 claims 1
- 150000002500 ions Chemical class 0.000 claims 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 211
- 210000004027 cell Anatomy 0.000 description 68
- 239000002609 medium Substances 0.000 description 45
- 235000010633 broth Nutrition 0.000 description 32
- 125000003275 alpha amino acid group Chemical group 0.000 description 14
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 14
- 229940045189 glucose-6-phosphate Drugs 0.000 description 13
- LFLUCDOSQPJJBE-UHFFFAOYSA-K 3-phosphonatooxypyruvate(3-) Chemical compound [O-]C(=O)C(=O)COP([O-])([O-])=O LFLUCDOSQPJJBE-UHFFFAOYSA-K 0.000 description 12
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 10
- 108091033319 polynucleotide Proteins 0.000 description 10
- 102000040430 polynucleotide Human genes 0.000 description 10
- 239000002157 polynucleotide Substances 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 6
- 229930027917 kanamycin Natural products 0.000 description 6
- 229960000318 kanamycin Drugs 0.000 description 6
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 6
- 229930182823 kanamycin A Natural products 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 241000193830 Bacillus <bacterium> Species 0.000 description 5
- 239000004471 Glycine Substances 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 238000011143 downstream manufacturing Methods 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000004473 Threonine Substances 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 229940041514 candida albicans extract Drugs 0.000 description 4
- 238000012444 downstream purification process Methods 0.000 description 4
- 101150097303 glyA gene Proteins 0.000 description 4
- 101150079604 glyA1 gene Proteins 0.000 description 4
- 150000007523 nucleic acids Chemical group 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229960002898 threonine Drugs 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 239000012138 yeast extract Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000186216 Corynebacterium Species 0.000 description 3
- 241000186226 Corynebacterium glutamicum Species 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 108010043428 Glycine hydroxymethyltransferase Proteins 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- 241000194036 Lactococcus Species 0.000 description 3
- 241000589516 Pseudomonas Species 0.000 description 3
- 102000019394 Serine hydroxymethyltransferases Human genes 0.000 description 3
- 241000187747 Streptomyces Species 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 239000012527 feed solution Substances 0.000 description 3
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 3
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- NQEQTYPJSIEPHW-MNOVXSKESA-N (1S,2R)-1-C-(indol-3-yl)glycerol 3-phosphate Chemical compound C1=CC=C2C([C@H](O)[C@@H](COP(O)(O)=O)O)=CNC2=C1 NQEQTYPJSIEPHW-MNOVXSKESA-N 0.000 description 2
- 241000194108 Bacillus licheniformis Species 0.000 description 2
- 241000046135 Cedecea Species 0.000 description 2
- 241000588923 Citrobacter Species 0.000 description 2
- 241000607473 Edwardsiella <enterobacteria> Species 0.000 description 2
- 241000588914 Enterobacter Species 0.000 description 2
- 241000588698 Erwinia Species 0.000 description 2
- 101100420922 Escherichia coli (strain K12) sdaB gene Proteins 0.000 description 2
- 101100099027 Escherichia coli (strain K12) tdcG gene Proteins 0.000 description 2
- 241001646716 Escherichia coli K-12 Species 0.000 description 2
- 241000588731 Hafnia Species 0.000 description 2
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 2
- 239000007836 KH2PO4 Substances 0.000 description 2
- 241000588748 Klebsiella Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229910017621 MgSO4-7H2O Inorganic materials 0.000 description 2
- 241000588771 Morganella <proteobacterium> Species 0.000 description 2
- 241000588769 Proteus <enterobacteria> Species 0.000 description 2
- 241000589776 Pseudomonas putida Species 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 241000607720 Serratia Species 0.000 description 2
- 244000057717 Streptococcus lactis Species 0.000 description 2
- 235000014897 Streptococcus lactis Nutrition 0.000 description 2
- 241000187432 Streptomyces coelicolor Species 0.000 description 2
- 241000187392 Streptomyces griseus Species 0.000 description 2
- 241000187398 Streptomyces lividans Species 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 241000607734 Yersinia <bacteria> Species 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- CJNBYAVZURUTKZ-UHFFFAOYSA-N hafnium(IV) oxide Inorganic materials O=[Hf]=O CJNBYAVZURUTKZ-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 101150100082 sdaA gene Proteins 0.000 description 2
- 238000011218 seed culture Methods 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 1
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000589291 Acinetobacter Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000607469 Arsenophonus Species 0.000 description 1
- 241000193744 Bacillus amyloliquefaciens Species 0.000 description 1
- 241001249117 Bacillus mojavensis Species 0.000 description 1
- 241001167516 Biostraticola Species 0.000 description 1
- 241001236205 Brenneria Species 0.000 description 1
- 241001453698 Buchnera <proteobacteria> Species 0.000 description 1
- 241001622845 Budvicia Species 0.000 description 1
- 241001622847 Buttiauxella Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000805495 Cosenzaea Species 0.000 description 1
- 241000989055 Cronobacter Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 241001187099 Dickeya Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 241000131486 Ewingella Species 0.000 description 1
- 101150039774 GAPA1 gene Proteins 0.000 description 1
- 241000626621 Geobacillus Species 0.000 description 1
- 241001637593 Gibbsiella Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241000588752 Kluyvera Species 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001647840 Leclercia Species 0.000 description 1
- 241001622839 Leminorella Species 0.000 description 1
- 241001085384 Lonsdalea Species 0.000 description 1
- 241000762023 Mangrovibacter Species 0.000 description 1
- 241000043364 Moellerella Species 0.000 description 1
- 241001622836 Obesumbacterium Species 0.000 description 1
- 241000520272 Pantoea Species 0.000 description 1
- 241000531155 Pectobacterium Species 0.000 description 1
- 241000946806 Phaseolibacter Species 0.000 description 1
- 102000001105 Phosphofructokinases Human genes 0.000 description 1
- 108010069341 Phosphofructokinases Proteins 0.000 description 1
- 241001148062 Photorhabdus Species 0.000 description 1
- 241000607000 Plesiomonas Species 0.000 description 1
- 241000588768 Providencia Species 0.000 description 1
- 101100282114 Pseudomonas aeruginosa (strain UCBPP-PA14) gap2 gene Proteins 0.000 description 1
- 241001478280 Rahnella Species 0.000 description 1
- 241000321184 Raoultella Species 0.000 description 1
- 241000320040 Samsonia Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000128154 Shimwellia Species 0.000 description 1
- 241001660101 Sodalis Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 241001622829 Tatumella Species 0.000 description 1
- 241000384691 Thorsellia Species 0.000 description 1
- 241000043398 Trabulsiella Species 0.000 description 1
- 229920004482 WACKER® Polymers 0.000 description 1
- 241000498989 Wigglesworthia Species 0.000 description 1
- 241000043486 Yokenella Species 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000002210 biocatalytic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 108010062049 chirobiotic T Proteins 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 101150091570 gapA gene Proteins 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-M hydrosulfide Chemical compound [SH-] RWSOTUBLDIXVET-UHFFFAOYSA-M 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229930029653 phosphoenolpyruvate Natural products 0.000 description 1
- DTBNBXWJWCWCIK-UHFFFAOYSA-K phosphonatoenolpyruvate Chemical compound [O-]C(=O)C(=C)OP([O-])([O-])=O DTBNBXWJWCWCIK-UHFFFAOYSA-K 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 238000011027 product recovery Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003464 sulfur compounds Chemical class 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 101150059846 trpS gene Proteins 0.000 description 1
- 101150004782 trpS2 gene Proteins 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
- C12P13/06—Alanine; Leucine; Isoleucine; Serine; Homoserine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
- C12P13/12—Methionine; Cysteine; Cystine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/02—Monosaccharides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/02—Preparation of oxygen-containing organic compounds containing a hydroxy group
- C12P7/04—Preparation of oxygen-containing organic compounds containing a hydroxy group acyclic
- C12P7/18—Preparation of oxygen-containing organic compounds containing a hydroxy group acyclic polyhydric
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
- C12P7/42—Hydroxy-carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
- C12Y207/01002—Glucokinase (2.7.1.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
- C12Y207/01105—6-Phosphofructo-2-kinase (2.7.1.105)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y401/00—Carbon-carbon lyases (4.1)
- C12Y401/02—Aldehyde-lyases (4.1.2)
- C12Y401/02013—Fructose-bisphosphate aldolase (4.1.2.13)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y402/00—Carbon-oxygen lyases (4.2)
- C12Y402/01—Hydro-lyases (4.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y503/00—Intramolecular oxidoreductases (5.3)
- C12Y503/01—Intramolecular oxidoreductases (5.3) interconverting aldoses and ketoses (5.3.1)
- C12Y503/01001—Triose-phosphate isomerase (5.3.1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y503/00—Intramolecular oxidoreductases (5.3)
- C12Y503/01—Intramolecular oxidoreductases (5.3) interconverting aldoses and ketoses (5.3.1)
- C12Y503/01009—Glucose-6-phosphate isomerase (5.3.1.9)
Definitions
- the present disclosure describes methods for producing L-cysteine and/or L-cystine comprising converting L-serine in a fermentation medium produced by a genetically engineered host cell into L-cysteine and/or L-cystine by contacting the L-serine with a pyridoxal 5-phosphate (PLP)- dependent enzyme in the presence of the source of sulfur.
- PPP pyridoxal 5-phosphate
- the resulting fermentation media compositions comprising said medium, microbial cells genetically modified to produce the L-cysteine and/or L-cystine and cell cultures of such genetically modified microbail cells.
- L-cysteine is widely used as a pre-cursor in the food, pharmaceutical and personal-care industries, and the estimated annual production of L-cysteine in 2015 was approx. 14000 tons.
- L-cysteine is primarily produced by acid hydrolysis of feathers and hair (Hashim et al., 2014). This process employs 32 L of concentrated HCI per kg of L-cysteine and is therefore not only expensive, but also creates a lot of acidic wastewater (Hashim et al., 2014).
- the end-product is known to contain impurities of animal and even human origin known to cause allergies.
- TrpS tryptophan synthase
- PBP pyridoxal 5-phosphate
- the a-subunit of tryptophan synthase converts indole-3-glycerol phosphate to indole and D-glyceraldehyde-3-phosphate.
- the indole is transported to the p-subunit via a substrate tunnel, where it reacts with L-serine in the presence of the cofactor PLP, to generate tryptophan and water (Raboni et al., 2009).
- E. coli strains capable of producing L-serine titers >50 g/L via fermentation have previously bee described for example in US20210095245 or US10513682. Summary
- TrpS betasubunit of TrpS is highly promiscuous and accept an array of different nucleophilic substrates and that amongst the nucleophiles accepted are the hydrogen sulfide ion which, in the presence of TrpS, can react with L-serine to produce L-cysteine.
- TrpS form E. coli can be shown to effectively produce L-cysteine from purified L-serine in the presence of sodium hydrogen sulfide and the PLP enzyme co-factor.
- fermentation broths comprising L-serine produced by fermenting a microorganism genetically modified to produce L-serine, said broths having an optical density (OD 600 nm) of up to and above 40 and a serine concentration of up to and above >50 g/L, could be used for making enzymatically converted L-cysteine and/or L-cystine and that the method was, in efficiency, comparable to using pure L-serine as a substrate.
- TrpS catalysed the conversion of L- serine in the fermentation media at a rate comparable to the conversion of pure L-serine.
- the disclosure describes a method for producing L-cysteine and/or L-cystine comprising: a) providing a fermentation medium comprising serine from of a genetically engineered host cell producing said serine; b) providing one or more sources of sulfur; c) providing one or more pyridoxal 5-phosphate (PLP)-dependent enzymes capable of converting serine into cysteine and/or cystine in the presence of the source of sulfur; d) contacting the serine in the fermentation medium with the pyridoxal 5-phosphate (PLP)- dependent enzyme in the presence of PLP and the source of sulfur under conditions allowing the serine to be converted into cysteine and/or cystine; and optionally e) recovering and/or isolating the cysteine and/or cystine
- the disclosure describes a fermentation medium comprising L-cysteine and/or L-cystine, obtainable from the method as described herein.
- composition comprising the fermentation medium described herein and one or more agents, additives and/or excipients.
- the disclosure describes a microbial host cell genetically modified to produce L-cysteine and/or L-cystine, wherein the host cell expresses a heterologous gene encoding a pyridoxal 5-phosphate (PLP)-dependent enzyme and comprises an operative biosynthetic pathway capable of producing L-serine, said pathway comprising one or more pathway polypeptides selected from: a) glucokinase (glk) phosphorylating glucose to glucose-6-phosphate; b) phosphoglucose isomerase (pgi) isomerizing glucose-6-phosphate to fructose-6-phosphate; c) phosphofructokinase 2(pfkB) phosphorylating fructose-6-phosphate to fructose-1.6- bisphosphate; d) fructose-bisphosphate aldolase class 1 (fbaB) or fructose-bisphosphate aldolase class 2 (f
- Figure 1 shows a reaction scheme for the R-subunit of tryptophan synthase
- top The natural reaction catalysed by the R-subunit of tryptophan synthase where the indole is transported to the p-subunit via a substrate tunnel, where it reacts with L-serine in the presence of the cofactor PLP, to generate tryptophan and water.
- Bottom The reaction of the present disclosure for producing L-cysteine from L-serine and sodium hydrogen sulfide in the presence of PLP. Upon oxidation, cysteine may subsequently be converted to its dimeric form cystine.
- Figure 2 shows the production of L-serine by fermentation by a strain of E. coli.
- E. coli growth as a function of time for a representative serine producing fermentation.
- Serine titers as a function of time for a representative serine producing fermentation.
- FIG. 3 shows the expression of E. coli tryptophan synthase.
- (Top) Plasmid map of the plasmid used to express the trpS complex (trpA and trpB) from E. coli.
- (Bottom) SDS-PAGE analysis of TrpS expression. Distinct bands of overexpressed proteins are visible at approx. 30 and 43 kDa, which correlates well with the expected mass of nHis-trpA (29.8 kDa) and trpB (43 kDa), respectively.
- Figure 4 shows the fermentation of Cys_39 producing TrpS.
- the feed volume scheme resulting from a standard DO-sat controlled fermentation of Cys_39 to generate biomass for cysteine production.
- Cys_39 growth as a function of time for a representative Cys_39 DO-stat controlled fermentation.
- Figure 5 to 7 shows the conversion of L-serine to L-cysteine and L-cystine using pure L-serine and L- serine fermentation broth as substrates. Results from pure serine are shown in gray, and results from the serine fermentation broth are shown in black.
- FIG 8 shows a blok flow diagram of the designed serine downstream purification process.
- the serine broth used as a TrpS substrate in the examples is also indicated in the diagram.
- Figure 9 shows the metabolic pathway from glucose to cysteine.
- Any EC numbers used herein refers to Enzyme Nomenclature 1992 from NC-IUBMB, Academic Press, San Diego, California, including 30 supplements 1-5 published in Eur. J. Bio-chem. 1994, 223, 1- 5; Eur. J. Biochem. 1995, 232, 1-6; Eur. J. Biochem. 1996, 237, 1-5; Eur. J. Biochem. 1997, 250, 1-6; and Eur. J. Biochem. 1999, 264, 610-650; respectively.
- the nomenclature is regularly supplemented and updated; see e.g. http://enzyme.expasy.org/.
- the term "PEP" as used herein refers to phosphoenol pyruvate.
- PLP-dependent enzymes refers to any PLP dependent enzyme catalyzing the reaction of L-serine and sulfur containing reactant into L-cysteine.
- glucose-6-phosphate refers to an enzyme catalyzing the reaction of phosphorylating glucose into glucose-6-phosphate.
- phosphoglucose isomerase or pgi refers to an enzyme catalyzing the reaction of isomerizing glucose-6-phosphate into fructose-6-phosphate
- phosphofructokinase or pfkB refers to an enzyme catalyzing the reaction of phosphorylating fructose-6-phosphate into fructose-1.6-bisphosphate.
- fructose-bisphosphate aldolase calss 1 or 2 or fbaB or fbaA refers to enzymes splitting fructose 1,6-bisphosphate into dihydroxyacetone phosphate and glyceraldehyde 3-phosphate.
- triosephosphate isomerase or tpiA refers to an enzyme catalyzing the reaction of converting dihydroxyacetone phosphate into D-glyceraldehyde-3-phosphate.
- glycosylaldehyde-3-phosphate dehydrogenase A or gapA refers to an enzyme catalyzing the reaction of oxidatively phosphorylating D-glyceraldehyde 3-phosphate (G3P) into 1,3-bisphosphoglycerate (BPG) using the cofactor NAD.
- glycosylaldehyde-3-phosphate dehydrogenase or gapC refers to an enzyme catalyzing the reaction of converting D-glyceraldehyde 3-phosphate into 1,3- bisphosphoglyceric acid.
- phosphoglycerate kinase or pgk refers to an enzyme catalyzing the reaction of dephosphorylating 1,3-bisphosphoglyceric acid into generate 3-phospho-D-glycerate.
- D-3-phosphoglycerate dehydrogenase or serA refers to an enzyme catalyzing the reaction of oxidizing 3-phospho-D-glycerate into 3-phosphohydroxypyruvate.
- phosphoserine aminotransferase or serC refers to an enzyme catalyzing the reaction of converting 3-phosphohydroxypyruvate into phosphoserine.
- phosphoserine phosphatase as used herein refers to an enzyme catalyzing the reaction of dephosphorylating phosphoserine into L-serine.
- heterologous or recombinant or “genetically modified” and their grammatical equivalents as used herein interchangeably refers to entities "derived from a different species or cell".
- a heterologous or recombinant polynucleotide gene is a gene in a host cell not naturally containing that gene, i.e. the gene is from a different species or cell type than the host cell.
- microbial host cells refers to microbial host cells comprising and expressing heterologous or recombinant polynucleotide genes.
- biosynthetic pathway as used herein is intended to mean two or more enzymes acting sequentially in a live cell to convert chemical substrate(s) into chemical product(s).
- Enzymes are characterized by having catalytic activity, which can change the chemical structure of the substrate(s).
- An enzyme may have more than one substrate and produce more than one product.
- the enzyme may also depend on cofactors, which can be inorganic chemical compounds or organic compounds such as proteins for example enzymes (co-enzymes).
- operative biosynthetic pathway refers to a metabolic pathway that occurs in a live recombinant host, as described herein.
- in vivo refers to within a living cell or organism, including, for example animal, a plant or a microorganism.
- in vitro refers to outside a living cell or organism, including, without limitation, for example, in a microwell plate, a tube, a flask, a beaker, a tank, a reactor and the like.
- substrate or "precursor”, as used herein refers to any compound that can be converted into a different compound.
- substrates and/or precursors include both compounds generated in situ by a enzymatic reaction in a cell or exogenously provided compounds, such as exogenously provided organic molecules which the host cell can metabolize into a desired compound.
- Term "endogenous” or “native” as used herein refers to a gene or a polypepetide in a host cell which originates from the same host cell.
- deletion refers to manipulation of a gene so that it is no longer expressed in a host cell.
- disruption refers to manipulation of a gene or any of the machinery participating in the expression the gene, so that it is no longer expressed in a host cell.
- the term "attenuation” as used herein refers to manipulation of a gene or any of the machinery participating in the expression the gene, so that it the expression of the gene is reduced as compared to expression without the manipulation.
- isolated refers to any compound, which by means of human intervention, has been put in a form or environment that differs from the form or environment in which it is found in nature.
- Isolated compounds include but is no limited to compounds of the disclosure for which the ratio of the compounds relative to other constituents with which they are associated in nature is increased or decreased. In an important embodiment the amount of compound is increased relative to other constituents with which the compound is associated in nature.
- the compound of the disclosure may be isolated into a pure or substantially pure form.
- a substantially pure compound means that the compound is separated from other extraneous or unwanted material present from the onset of producing the compound or generated in the manufacturing process.
- Such a substantially pure compound preparation contains less than 10%, such as less than 8%, such as less than 6%, such as less than 5%, such as less than 4%, such as less than 3%, such as less than 2%, such as less than 1 %, such as less than 0.5% by weight of other extraneous or unwanted material usually associated with the compound when expressed natively or recombinantly.
- the isolated compound is at least 90% pure, such as at least 91% pure, such as at least 92% pure, such as at least 93% pure, such as at least 94% pure, such as at least 95% pure, such as at least 96% pure, such as at least 97% pure, such as at least 98% pure, such as at least 99% pure, such as at least 99.5% pure, such as 100 % pure by weight.
- % identity is used herein about the relatedness between two amino acid sequences or between two nucleotide sequences.
- the term “% identity” as used herein about amino acid sequences refers to the degree of identity in percent between two amino acid sequences obtained when using the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, J. Mol. Biol. 48: 443- 453) as implemented in the Needle program of the EMBOSS package (EMBOSS: The European Molecular Biology Open Software Suite, Rice et al., 2000, Trends Genet. 16: 276-277), preferably version 5.0.0 or later.
- the parameters used are gap open penalty of 10, gap extension penalty of 0.5, and the EBLOSUM62 (EMBOSS version of BLOSUM62) substitution matrix.
- the output of Needle labeled "longest identity" (obtained using the -nobrief option) is used as the percent identity and is calculated as follows: identical amino acid residues - x 100 Length of alignment — total number of gaps in alignment
- % identity refers to the degree of identity in percent between two nucleotide sequences obtained when using the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, supra) as implemented in the Needle program of the EMBOSS package (EMBOSS: The European Molecular Biology Open Software Suite, Rice et al., 2000, supra), preferably version 5.0.0 or later.
- the parameters used are gap open penalty of 10, gap extension penalty of 0.5, and the EDNAFULL (EMBOSS version of NCBI NUC4.4) substitution matrix.
- the protein sequences of the present disclosure can further be used as a "query sequence" to perform a search against sequence databases, for example to identify other family members or related sequences. Such searches can be performed using the BLAST programs.
- Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov).
- BLASTP is used for amino acid sequences and BLASTN for nucleotide sequences.
- the degree of local identity between the amino acid sequence query or nucleic acid sequence query and the retrieved homologous sequences is determined by the BLAST program. However only those sequence segments are compared that give a match above a certain threshold. Accordingly, the program calculates the identity only for these matching segments. Therefore, the identity calculated in this way is referred to as local identity.
- expression includes any step involved in the production of a polypeptide including, but not limited to, transcription, post-transcriptional modification, translation, post- translational modification, and secretion.
- expression vector refers to a DNA molecule, either single- or double stranded, either linear or circular, which comprises a polynucleotide encoding a polypeptide and is operably linked to control sequences that provide for its expression.
- Expression vectors include expression cassettes for the integration of genes into a host cell as well as plasmids and/or chromosomes comprising such genes.
- host cell refers to any cell type that is susceptible to transformation, transfection, transduction, or the like with a nucleic acid construct or expression vector comprising a polynucleotide of the present disclosure.
- Host cell encompasses any progeny of a parent cell that is not identical to the parent cell due to mutations that occur during replication.
- polynucleotide construct or “nucleic acid construct” refers to a polynucleotide, either single- or double stranded, which is separated from its naturally occurring environment and/or is modified to contain segments of nucleic acids in a manner that would not otherwise exist in nature or which is synthetic, and which comprises a polynucleotide encoding a polypeptide and one or more control sequences.
- operably linked refers to a configuration in which a control sequence is placed at an appropriate position relative to the coding polynucleotide such that the control sequence directs expression of the coding polynucleotide.
- nucleotide sequence and “polynucleotide” are used herein interchangeably.
- cell culture refers to a culture medium comprising a plurality of host cells of the disclosure.
- a cell culture may comprise a single strain of host cells or may comprise two or more distinct host cell strains.
- the culture medium may be any medium that may comprise a recombinant host, e.g., a liquid medium (i.e., a culture broth) or a semi-solid medium, and may comprise additional components, e.g., a carbon source such as dextrose, sucrose, glycerol, or acetate; a nitrogen source such as ammonium sulfate, urea, or amino acids; a phosphate source; vitamins; trace elements; salts; amino acids; nucleobases; and yeast extract.
- a recombinant host e.g., a liquid medium (i.e., a culture broth) or a semi-solid medium
- additional components e.g., a carbon source such as dextrose, sucrose, glycerol,
- fermentation medium refers to any medium in which a genetically modified host is producing or has produced L-serine.
- a fermentation medium may contain solid cellular material (broths) or may be partially or wholly free of solid cellular material.
- sources of sulfur refers to any compound comprising sulfur in a form which the pyridoxal 5-phosphate (PLP)-dependent enzyme can covalently bind to serine to from cysteine.
- the first aspect of the present disclosure concerns a method for producing cysteine and/or cystine comprising a) providing a fermentation medium and/or broth comprising serine from of a genetically engineered host cell producing said serine, and optionally comprising metabolites and/or cells and/or cell debris from the serine producing host cell; b) providing one or more sources of sulfur; c) providing one or more pyridoxal 5-phosphate (PLP)-dependent enzymes; d) contacting the serine in the fermentation medium with the pyridoxal 5-phosphate (PLP)- dependent enzyme in the presence of the source of sulfur under conditions allowing the serine to be converted into cysteine and/or cystine; and optionally e) recovering and/or isolating the cysteine and/or cystine.
- a method for producing cysteine and/or cystine comprising a) providing a fermentation medium and/or broth comprising serine from of a genetically engineered host cell producing said serine, and optionally comprising metabolites and/or
- the method for producing cysteine and/or cystine comprising a) providing a fermentation medium comprising serine from of a genetically engineered host cell producing said serine; b) providing one or more sulfur sources which are NaSH; NajS; and/or H2S c) providing a pyridoxal 5-phosphate (PLP)-dependent enzyme TrpS comprising i) an enzyme subunit having an amino acid sequence comprised in SEQ ID NO: 13 (trpB) and ii) an enzyme subunit having an amino acid sequence comprised in SEQ.
- PBP pyridoxal 5-phosphate
- ID NO: 14 wherein the subunits, alone and together, are capable of converting serine into cysteine and/or cystine in the presence of the one or more sulfur sources; d) contacting the serine in the fermentation medium with the pyridoxal 5-phosphate (PLP)- dependent enzyme TrpS in the presence of PLP and the one or more sulfur sources under conditions allowing the serine to be converted into cysteine and/or cystine; and e) optionally recovering and/or isolating the cysteine and/or cystine.
- PLP pyridoxal 5-phosphate
- Cysteine is usually in equilibrium with cystine through oxidation, but in further embodiment the method can also comprise steps with the aim of converting the monomeric cysteine to the dimeric cystine or shifting the equilibriums in either direction depending on which of cysteine or cystine that are most desirable.
- the fermentation medium used in the methods described herein is a broth which comprises components of the host cells and/or components produced by the host cells from the extracellular or intracellular matrix or both, components produced by the host cells includes particularly metabolites of the host cell production of serine such as those selected from glucose-6-phosphate, fructose-l,6-phosphate, glyceraldehyde-3-phosphate, dihydroxyacetone phosphate, 1,3-diphosphoglycerate, 3-phosphoglycerate, 3-phosphopyrovate, and/or 3- phosphoserine.
- serine such as those selected from glucose-6-phosphate, fructose-l,6-phosphate, glyceraldehyde-3-phosphate, dihydroxyacetone phosphate, 1,3-diphosphoglycerate, 3-phosphoglycerate, 3-phosphopyrovate, and/or 3- phosphoserine.
- such components of the fermentation mediums can also comprise by one or more components selected from: a) a carbon source, optionally selected from glycerol; carbohydrates (such as monosaccharides and/or disaccharides; complex sources (such as molasses, fats and oils, and/or starch biomass; b) a nitrogen source, optionally selected from ammonium compounds, nitrates, Urea and/or Amino acids such as alanine arginine, Leucine, and/or D,L-aspartate; c) a phosphate source, optionally selected from potassium phosphate; d) a sulfate source, optionally selected from ammonium sulfate and/or magnesium sulfate; e) trace elements, optionally selected from Fe, Zn, Cu, Mn, Mo, Co, and/or Ni.
- a carbon source optionally selected from glycerol
- carbohydrates such as monosaccharides and/or disaccharides; complex sources (such as
- the fermentation medium comprises ammonium ions, optionally between 0,1 g/L to 20 g/L, optionally between 0,5 g/L to 15 g/L, optionally between 1 g/L to 10 g/L, optionally between 2 g/L to 5 g/L of ammonium ions.
- the fermentation medium comprises phosphate ions, optionally between 0,01 g/L to 10 g/L, optionally between 0,02 g/L to 5 g/L, optionally between 0,05 g/L to 2 g/L of phosphate ions.
- the fermentation medium comprises proteins, DNA and RNA liberated by the host cells.
- the fermentation medium comprises live cells and/or cell debris, optionally between 0,1 %wt to 75 %wt, optionally between 0,5 %wt to 50 %wt, optionally between 1 %wt to 40 %wt, optionally between 2 %wt to 35 %wt, optionally between 3 %wt to 30 %wt, optionally between 5 %wt to 25 %wt, optionally between 10 %wt to 20 %wt.
- live cells and/or cell debris optionally between 0,1 %wt to 75 %wt, optionally between 0,5 %wt to 50 %wt, optionally between 1 %wt to 40 %wt, optionally between 2 %wt to 35 %wt, optionally between 3 %wt to 30 %wt, optionally between 5 %wt to 25 %wt, optionally between 10 %wt to 20 %wt.
- the fermentation medium comprises N-acetyl serine, optionally between 0,05 g/L to 20 g/L, optionally between 0,1 g/L to 10 g/L, optionally between 0,5 g/L to 2 g/L of N-acetyl serine.
- the fermentation medium comprises pyridoxal 5-phosphate (PLP) cofactor, suitable in amounts of at least 0,01 pM, such as at least 0,05 pM, such as at least 0,1 pM, such as at least 0,5 pM, such as at least 1 pM, such as at least 5 pM, such as at least 10 pM, such as at least 50 pM, such as at least 100 pM, such as at least 250 pM, such as at least 500 pM, such as at least 1 mM but suitably not higher than 10 mM.
- PRP pyridoxal 5-phosphate
- the fermentation medium comprises serine, in amounts which suitably priorto any conversion of serine into cysteine is at least 10 g/L serine, such as at least 20 g/L, such as at least 30 g/L, such as at least 40 g/L, such as at least 50 g/L, such as at least 60 g/L, such as at least 70 g/L, such as at least 70 g/L, such as at least 80 g/L, such as at least 90 g/L, but suitably below 500 g/L, such as below 250 g/L, such as below 200 g/L, such as below 150 g/L, such as below 125 g/L, such as below 100 g/L.
- serine in amounts which suitably priorto any conversion of serine into cysteine is at least 10 g/L serine, such as at least 20 g/L, such as at least 30 g/L, such as at least 40 g/L, such as at least 50 g/L, such as at
- a particular amount is between 50 to 100 g/L of serine which is obtainable in high yield fermentations.
- concentration of serine in the fermentation medium is lowered, while in other embodiments where a host cell continuously produces new serine, concentrations of serine may reach a stady state within the aforementions ranges.
- the fermentation providing the fermentation medium is advantageously progressed to a stage where the optical density (OD) at 600 nm is at least 1, such as at least 2, such as at least 4, such as at least 6, such as at least 8, such as at least 10, such as at least 15, such as at least 20, inducating the concentration of cells or cellular debris is so high as to also provide for a high concentration of serine.
- the optical density (OD) at 600 nm is at least 1, such as at least 2, such as at least 4, such as at least 6, such as at least 8, such as at least 10, such as at least 15, such as at least 20, inducating the concentration of cells or cellular debris is so high as to also provide for a high concentration of serine.
- the the one or more sources of sulfur can be any compound comprising sufur and which the pyridoxal 5-phosphate (PLP)-dependent enzyme is capable of using for covalendly binding hydrogen sulfide (-SH) to serine.
- Such sulfur compounds include any compound which in solution can generate such as H2S, S 2- , and/or NaHS.
- the one or more sources of sulfur comprises hydrogen sulfide.
- the source of sulfur comprises a basic compound, such as a strongly basic compound.
- the source of sulfur comprises an acidic compound, such as a strongly acidic compound. In some embodiments it is desired to maintain a certain minimum level of the the sulfur source during at least the major period of conversion of serine to cysteine.
- a concentration of the source of sulfur of at least 0,1 % wt, such as least 0,5 % wt, such as least 1 % wt, such as least 2 % wt, such as least 4 % wt, such as least 6 % wt, such as least 8 % wt, such as least 10 % wt, but suitably less than 15 % wt.
- the pyridoxal 5-phosphate (PLP)-dependent enzyme used the method described can be derived from a bacterium, such as a strain of the genus Eschericia, particularly of the species Eschericia coli.
- the pyridoxal 5-phosphate (PLP)-dependent enzyme is selected from lyases (EC 4.-.-.-), carbon oxygen lyases (EC 4.2.-.-), and/or hydro-lyases (EC 4.2.1.-).
- the pyridoxal 5-phosphate (PLP)-dependent enzyme comprises a fold type II configuration such as described in (Percudani 2009, B6 database).
- the pyridoxal 5-phosphate (PLP)-dependent enzyme is a Tryptophan synthase (TrpS), especially an E. coli TrpS, optionally comprising an amino acid sequence which has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to one or more of SEQ ID NO: 13 (trpB), 14 (trpA), 15 (trpB) or 16 (trpA).
- TrpS Tryptophan synthase
- the pyridoxal 5-phosphate (PLP)-dependent enzyme comprises one or more mutations outside the PLP binding site and/or outside the substrate binding site.
- the PLP binding site of the pyridoxal 5-phosphate (PLP)-dependent enzyme suitably comprises one or more amino acid moieties corresponding to position H86, K87, Q114, T190, C230, G232, G233, G234, S235, N236, A237, G303, E350, S377, or G378 of SEQ.
- the substrate binding site of the pyridoxal 5-phosphate (PLP)-dependent enzyme suitably comprises one or more amino acid moieties corresponding to position N305, A112, Gill, T110, Q114, H115, G113, or E109 of SEQ ID NO: 15 or 16.
- the pyridoxal 5-phosphate (PLP)-dependent enzyme comprises one or more mutations selected from D47S and L81V in the corresponding amino acid sequence of SEQ. ID NO: 15 or 16 or conservative substitutions thereof.
- the method produces cysteine/cystine with high efficiency and in some embodiments at least 50%, such as at least 75%, such as at least 85%, such as at least 90%, such as at least 95%, such as at least 98% of the serine in the fermentation medium is converted to cysteine and/or cystine.
- the method can further comprise steps for generating serine from one or more precursors including one or more steps selected from a) Phosphorylation of glucose by Glucokinase (glk) to generate glucose-6-phosphate; b) Isomerisation of glucose-6-phosphate by phosphoglucose isomerase (pgi) to generate fructose- 6-phosphate; c) Phosphorylation of fructose-6-phosphate by phosphofructokinase 2(pfkB) to generate fructose- 1.6-bisphosphate; d) Splitting of fructose 1,6-bisphosphate by fructose-bisphosphate aldolase class 1 (fbaB) or fructose-bisphosphate aldolase class 2 (fbaA) into dihydroxyacetone phosphate and glyceraldehyde 3-phosphate; e) Conversion of dihydroxyacetone phosphate by triosephosphate isomerase (tpiA) to
- the method comprises: a) oxidation of 3-phospho-D-glycerate by D-3-phosphoglycerate dehydrogenase (serA) to 3- phosphohydroxypyruvate; b) conversion of 3-phosphohydroxypyruvate by phosphoserine aminotransferase (serC) to phosphoserine; or c) dephosphorylation of phosphoserine by phosphoserine phosphatase (serB) to serine.
- the glucokinase (glk) has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the Glucokinase comprised in SEQ ID NO: 1.
- the phosphoglucose isomerase (pgi) has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the phosphoglucose isomerase (pgi) comprised in SEQ. ID NO: 2.
- the phosphofructokinase 2 has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the phosphofructokinase 2 (pfkB) comprised in SEQ ID NO: 3.
- the fructose-bisphosphate aldolase class 1 has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the fructose-bisphosphate aldolase comprised in SEQ ID NO: 4.
- the fructose-bisphosphate aldolase class 2 has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the fructose-bisphosphate aldolase comprised in SEQ ID NO: 5.
- the triosephosphate isomerase has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the triosephosphate isomerase comprised in SEQ ID NO: 6.
- the glyceraldehyde-3-phosphate dehydrogenase A has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the glyceraldehyde-3-phosphate dehydrogenase A comprised in SEQ ID NO: 7.
- the glyceraldehyde-3-phosphate dehydrogenase has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the glyceraldehyde-3-phosphate dehydrogenase comprised in SEQ ID NO: 8.
- the phosphoglycerate kinase (pgk) has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the phosphoglycerate kinase comprised in SEQ ID NO: 9.
- the D-3-phosphoglycerate dehydrogenase has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the D-3- phosphoglycerate dehydrogenase comprised in SEQ ID NO: 10.
- the phosphoserine aminotransferase has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the phosphoserine aminotransferase comprised in SEQ ID NO: 11.
- the phosphoserine phosphatase (serB) has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the phosphoserine phosphatase comprised in SEQ ID NO: 12.
- the serine hydroxymethyl transferase has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the serine hydroxymethyl transferase comprised in SEQ ID NO: 26.
- the pH in the fermentation medium during conversion of serine to cysteine is suitably kept from about 6 to about 10, such as from about 7 to about 9, allowing the pH to fluctuate around these end points with 0,1 pH.
- the temperature in the fermentation medium is kept from about 25°C to about 60°C, such as from about about 30°C to about 50°C, such as from about about 35°C to about 40°C, such as about 37°C allowing the temperature to fluctuate around these end points with 1 °C.
- the recovery and/or isolation of cysteine and/or cystine as described herein suitable comprise one or more steps selected from: a) Separation of any biomass from the fermentation medium b) contacting the fermentation medium with one or more adsorbent resins to obtain at least a portion of the produced cysteine and/or cystine; c) contacting the fermentation medium with one or more ion exchange or reversed-phase chromatography columns in order to obtain at least a portion of the cysteine and/or cystine; d) extracting the cysteine and/or cystine from the fermentation medium; and e) precipitating the cysteine and/or cystine from the fermentation medium by crystallization or evaporating the solvent of the liquid phase; and optionally isolating cysteine and/or cystine by filtration or gravity separation; thereby recovering and/or isolating the cysteine and/or cystine.
- a further aspect of the present disclosure concerns a fermentation medium comprising cysteine and/or cystine, obtainable from the method described herein.
- the fermentation medium can include one or more component selected from unspent PLP, unspent sulfur source; unspent serine, pyridoxal 5-phosphate (PLP)-dependent enzyme; as well as metabolites of the host cell production of serine such as those selected from glucose-6- phosphate, fructose-l,6-phosphate, glyceraldehyde-3-phosphate, dihydroxyacetone phosphate, 1,3- diphosphoglycerate, 3-phosphoglycerate, 3-phosphopyrovate, and/or 3-phosphoserine.
- unspent PLP unspent sulfur source
- unspent serine unspent serine
- pyridoxal 5-phosphate (PLP)-dependent enzyme as well as metabolites of the host cell production of serine such as those selected from glucose-6- phosphate, fructose-l,6-phosphate, g
- the fermentation medium can also include unspent components selected from: f) a carbon source, optionally selected from glycerol; carbohydrates (such as monosaccharides and/or disaccharides; complex sources (such as molasses, fats and oils, and/or starch biomass; g) a nitrogen source, optionally selected from ammonium compounds, nitrates, Urea and/or Amino acids such as alanine arginine, Leucine, and/or D,L-aspartate; h) a phosphate source, optionally selected from potassium phosphate; i) a sulfate source, optionally selected from ammonium sulfate and/or magnesium sulfate; or j) trace elements, optionally selected from Fe, Zn, Cu, Mn, Mo, Co, and/or Ni;
- the concentration of cysteine and/or cystine at least 0,1 % by weight, such as at least 0,5 % by weight, such as at least 1 % by weight, such as at least 5 % by weight, such as at least 10 % by weight, such as at least 15 % by weight.
- a further aspect of the present disclosure concerns a composition
- a composition comprising the fermentation medium described herein and one or more agents, additives and/or excipients.
- the fermentation medium is suitably further processed into a dry solid form or a stabilized liquid form, but removing water or other solvents
- a fermentation compound is a constituent of a fermentation medium or a compound produced by a fermentation process.
- non-limiting exemplary fermentation compounds are selected from glucose-6-phosphate, fructose-l,6-phosphate, glyceraldehyde-3-phosphate, dihydroxyacetone phosphate, 1,3-diphosphoglycerate, 3- phosphoglycerate, 3-phosphopyrovate, 3-phosphoserine, glycerol, monosaccharides, disaccharides, ammonium compounds, nitrates, urea, alanine, arginine, leucine, D-aspartate, potassium phosphate, ammonium sulfate, magnesium sulfate, Fe, Zn, Cu, Mn, Mo, Co, and/or Ni.
- a further aspect of the present disclosure concerns a microbial host cell genetically modified to produce cysteine and/or cystine, wherein the host cell expresses a heterologous gene encoding a pyridoxal 5-phosphate (PLP)-dependent enzyme and comprises an operative biosynthetic pathway capable of producing serine, said pathway comprising one or more pathway polypeptides selected from: a) glucokinase (glk) phosphorylating glucose to glucose-6-phosphate; b) phosphoglucose isomerase (pgi) isomerizing glucose-6-phosphate to fructose-6-phosphate; c) phosphofructokinase 2(pfkB) phosphorylating fructose-6-phosphate to fructose-1.6- bisphosphate; d) fructose-bisphosphate aldolase class 1 (fbaB) or fructose-bisphosphate aldolase class 2 (fbaA)
- PBP pyridox
- a microbial host cell genetically modified to produce cysteine and/or cystine wherein the host cell expresses heterologous genes encoding a pyridoxal 5-phosphate (PLP)-dependent enzyme TrpS comprising i) an enzyme subunit having an amino acid sequence comprised in SEQ ID NO: 13 (trpB) and ii) an enzyme subunit having an amino acid sequence comprised in SEQ.
- PBP pyridoxal 5-phosphate
- ID NO: 14 (trpA), further comprising an operative biosynthetic pathway capable of producing serine, said pathway comprising one or more pathway polypeptides selected from: a) glucokinase (glk) comprised in SEQ ID NO: 1 phosphorylating glucose to glucose-6-phosphate; b) phosphoglucose isomerase (pgi) comprised in SEQ.
- glk glucokinase
- pgi phosphoglucose isomerase
- ID NO: 2 isomerizing glucose-6-phosphate to fructose-6-phosphate; c) phosphofructokinase 2 (pfkB) comprised in SEQ ID NO: 3 phosphorylating fructose-6-phosphate to fructose-1.6-bisphosphate; d) fructose-bisphosphate aldolase class 1 (fbaB) comprised in SEQ ID NO: 4 or fructose-bisphosphate aldolase class 2 (fbaA) comprised in SEQ ID NO: 5 splitting fructose 1,6-bisphosphate into dihydroxyacetone phosphate and glyceraldehyde 3-phosphate; e) triosephosphate isomerase (tpiA) comprised in SEQ ID NO: 6 converting dihydroxyacetone phosphate to D-glyceraldehyde-3-phosphate; f) glyceraldehyde-3-phosphate dehydrogenase A (gapA) comprised in S
- the pyridoxal 5-phosphate (PLP)-dependent enzyme is in some embodiments Tryptophan synthase comprising an amino acid sequence which has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the Tryptophan synthase units comprised in SEQ ID NO: 13, 14, 15 or 16.
- the glucokinase (glk) has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the Glucokinase comprised in SEQ ID NO: 1.
- the phosphoglucose isomerase (pgi) has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the phosphoglucose isomerase (pgi) comprised in SEQ ID NO: 2.
- the phosphofructokinase 2 has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the phosphofructokinase 2 (pfkB) comprised in SEQ. ID NO: 3.
- the fructose-bisphosphate aldolase class 1 has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the fructose- bisphosphate aldolase comprised in SEQ ID NO: 4.
- the fructose-bisphosphate aldolase class 2 has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the fructose-bisphosphate aldolase comprised in SEQ ID NO: 5.
- the triosephosphate isomerase has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the triosephosphate isomerase comprised in SEQ ID NO: 6.
- the glyceraldehyde-3-phosphate dehydrogenase A has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the glyceraldehyde-3-phosphate dehydrogenase A comprised in SEQ ID NO: 7.
- the glyceraldehyde-3-phosphate dehydrogenase has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the glyceraldehyde-3-phosphate dehydrogenase comprised in SEQ ID NO: 8.
- the phosphoglycerate kinase (pgk) has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the phosphoglycerate kinase comprised in SEQ ID NO: 9.
- the D-3- phosphoglycerate dehydrogenase has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the D-3-phosphoglycerate dehydrogenase comprised in a sequence selected from the group consisting of: SEQ ID NO: 10, SEQ ID NO: 27 , SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46,
- the D-3-phosphoglycerate dehydrogenase has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the D-3- phosphoglycerate dehydrogenase comprised in: SEQ ID NO: 10.
- the phosphoserine aminotransferase (serC) has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the phosphoserine aminotransferase comprised in SEQ.
- the phosphoserine phosphatase has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the phosphoserine phosphatase comprised in SEQ ID NO: 12.
- the genetically modified host cell comprises and expresses one or more genes encoding the one or more pathway polypeptides, which genes are selected from the group of: a) a gene which has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the gene encoding the Tryptophan synthase comprised in SEQ ID NO: 13, 14, 15 or 16; b) a gene which has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the gene encoding the glucokinase comprised in SEQ ID NO: 1; c) a gene which has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least at least 99% identity, such
- one or more of the said genes and/or pathway polypeptides are heterologous to the host cell and moreover the host cell can comprise two or more copies of one or more of these genes or otherwise overexpressed.
- the host cell can comprise a transporter molecule facilitating transport of a precursor for or a product of the serine pathway.
- the host cell can also be further genetically modified to provide an increased amount of a substrate in the serine pathway, and/or one or more native or endogenous genes of the host cell can be deleted, disrupted and/or attenuated to increase production of serine. Still further the host cell can be further genetically modified to exhibit increased tolerance towards one or more substrates, intermediates, or products in the serine pathway.
- the one or more genes to be deleted, disrupted and/or attenuated to increase production of serine are selected from the group consisting of: sdaA (SEQ ID NO: 23), sdaB (SEQ ID NO: 24), tdcG (SEQ ID NO: 25), and glyA (SEQ ID NO: 26) or any homologs or paralogs thereof having at least 90% sequence identity thereto.
- the host cell according to the present disclosure is provided wherein one or more native or endogenous genes of the host cell are deleted, disrupted and/or attenuated, wherein the one or more genes are selected from the group consisting of: sdaA, sdaB, tdcG, and glyA.
- the host cell described herein is suitably prokaryotic or eukaryotic such as of the genus Escherichia, optionally of the species Escherichia coli or C. glutamicum.
- the host cell described herein is a Gram-positive or Gram-negative bacterium.
- bacteria which can be used according to the present disclosure belong to the Enterobacteriaceae family, such as bacteria belonging to a genus selected from the group consisting of Escherichia, Arsenophonus, Biostraticola, Brenneria, Buchnera, Budvicia, Buttiauxella, Cedecea, Citrobacter, Cosenzaea, Cronobacter, Dickeya, Edwardsiella, Enterobacter, Erwinia, Ewingella, Gibbsiella, Hafnia, Klebsiella, Leclercia, Leminorella, Lonsdalea, Mangrovibacter, Moellerella, Morganella, Obesumbacterium, Pantoea, Pectobacterium, Phaseolibacter, Photorhabdus, Plesiomonas, Proteus, Rahnella, Raoultella, Saccharobacter, Salmonella, Samsonia, Serratia, Shimwellia, Sodalis, Tatumella, Thorsellia
- the bacterium belongs to a genus selected from the group selected from Escherichia, Bacillus, Lactococcus, Lactobacillus, Clostridium, Corynebacterium, Geobacillus, Streptococcus, Pseudomonas, Streptomyces, Shigella, Acinetobacter, Citrobacter, Salmonella, Klebsiella, Enterobacter, Erwinia, Kluyvera, Serratia, Cedecea, Morganella, Hafnia, Edwardsiella, Providencia, Proteus and Yersinia.
- the bacterium belongs to the genus Escherichia.
- the bacterium is Escherichia coli.
- Non-limiting examples of a bacterium belonging to the genus Escherichia, which can be used to derive a host cell of the present disclosure are Escherichia coli K-12 (especially substrain MG1655 or W3110), BL21, W, or Crooks.
- the bacterium is Escherichia coli K-12.
- the bacterium belongs to the genus Corynebacterium.
- a non-limiting example of a bacterium of the genus Corynebacterium is Corynebacterium glutamicum.
- the bacterium is Corynebacterium glutamicum.
- the bacterium belongs to the genus Bacillus.
- a bacterium of the genus Bacillus are Bacillus subtitlis, Bacillus amyloliquefaciens, Bacillus licheniformis, and Bacillus mojavensis.
- the bacterium is Bacillus subtitlis.
- the bacterium is Bacillus licheniformis.
- the bacterium belongs to the genus Lactococcus.
- a non-limiting example of a bacterium of the genus Lactococcus is Lactococcus lactis.
- the bacterium is Lactococcus lactis.
- the bacterium belongs to the genus Streptomyces.
- a non-limiting examples of a bacterium of the genus Streptomyces are Streptomyces lividans, Streptomyces coelicolor, or Streptomyces griseus.
- the bacterium is Streptomyces lividans.
- the bacterium is Streptomyces coelicolor.
- the bacterium is Streptomyces griseus.
- the bacterium belongs to the genus Pseudomonas.
- a non-limiting example of a bacterium of the genus Pseudomonas is Pseudomonas putida.
- the bacterium is Pseudomonas putida.
- an additional aspect of the present disclosure concerns a cell culture, comprising host cell described herein and a fermentation medium and in some embodiments the methods described herein also include steps of: a) culturing the said cell culture at conditions allowing the host cell to produce serine and the pyridoxal 5-phosphate (PLP)-dependent enzyme; and b) feeding the source of sulfur to the fermentation medium.
- PRP pyridoxal 5-phosphate
- the said method can further comprise one or more steps selected from: a) culturing the cell culture under aerobic and/or anaerobic conditions b) culturing the cell culture under agitation; c) culturing the cell culture at a temperature of between 25 to 70 °C; d) culturing the cell culture at a pH of between 6-10; e) culturing the cell culture for between 10 hours to 30 days; and f) culturing the cell culture under fed-batch, repeated fed-batch, continuous, or semi-continuous conditions.
- the methods described herein can also include feeding one or more exogenous serine precursors to the cell culture.
- Chemicals used in the examples herein, e.g. for buffers and substrates, are commercial products of at least reagent grade.
- Dissolved oxygen tension was maintained at 20% and pH controlled at pH 7,0 +/-0,l using ammonia liquid (15-25% w/v).
- the batch media contained 2 g/L MgSO4-7H2O, 2 g/L KH2PO4, 10 g/L ammonium sulfate, 60mM glucose or carbohydrate equivalent based on C-mol basis, 2 g/L yeast extract, 0.6 g/L glycine, lx trace elements and 50 mg/L kanamycin. Onset of the fed- batch feeding was initiated by increase of the DO upon depletion of batch glucose.
- the feed solution contained 650 g/L glucose, 6 g/L glycine and 50 pg/mL kanamycin.
- Example 2 Generation of an E. coli BL21 (DE3) strain expressing tryptophan synthase
- a pSEVA27 vector backbone containing the two genes (trpA and trpB) encoding E. coli TrpS was constructed using uracil excision cloning as described in Cavaleiro et al., 2015. Briefly, a pSEVA27 vector backbone fragment was PCR amplified using the oCys_50 and oCys_51 primers (table 1), and TrpS was amplified from the genome of E. coli BI21(DE3).
- trpB was amplified using primers oCys_48 and oCys_53 (table 1) and trpA using primers oCys_49 and oCys_52 (table 1).
- Amplification of trpA using these primers generated an n-terminal hexahistidine tag.
- Each PCR reaction contained 200 nM of forward and reverse primer, 1 X Phusion U mastermix (Thermoscientific, Waltham, MA, USA) and approx. 1 ng of DNA template.
- the following PCR protocol was used for amplification: An initial denaturation step at 98°C for 40 seconds, followed by 20 cycles of denaturation at 98°C for 12 seconds, annealing at 60°C for 30 seconds, extension at 72°C for 60 seconds.
- the resulting PCR products were column purified (Nucleospin PCR clean up kit) and subjected to Dpnl (New England Biolabs, Ipswitch, MA, USA) digestion overnight.
- the digested products were column purified (Nucleospin PCR clean up kit) and concentration was measured using a Nanodrop instrument (Thermoscientific, Waltham, MA, USA).
- the resulting fragments were assembled using USER enzyme (New England Biolabs, Ipswitch, MA, USA) by incubation at 37°C for 30 min followed by 16°C for 25 min, using a molar ratio of vector to insert of 1:1.5. 2.5 pL of the USER mix was transformed into chemically competent E.
- coli DH5a cells New England Biolabs, Ipswitch, MA, USA
- 100 pL of the transformed cells plated on LB-kan plates A single colony was used to inoculate 10 ml of 2xYT media with 50 pg/ml Kanamycin, which was incubated O/N at 37°C and shaking at 250 rpm.
- Plasmid from the resulting culture was purified (Nucleospin plasmid purification kit) and the plasmid sequence verified by sanger sequencing (Eurofins Scientific, Germany). 100 ng of verified plasmid was transformed into chemically competent E.
- Example 3 Production of L-cysteine from L-serine and sodium hydrogen sulfide using tryptophan synthase
- the Cys_39 biomass was generated as follows: Seed cultures were grown aerobically in 2xYT medium containing 0.2% glucose, ImM glycine and supplemented with required antibiotics, or in fermentation media as detailed below, until at least an optical density at 600nm (OD600) above 5 was reached.
- Fed batch fermentation was performed at 32°C using a starting batch volume of 40% of the total working reactor volume.
- the seed inoculation was 2,5% of the batch volume.
- Dissolved oxygen tension (DO) was maintained at 30% and pH controlled at pH 7,0 +/-0,l using ammonia liquid (15-25% w/v).
- the batch media contained 2 g/L MgSO4-7H2O, 2 g/L KH2PO4, 5 g/L ammonium sulfate, 0.5 % Glucose and 0.5 % Glycerol glucose or carbohydrate equivalent based on C-mol basis, 5 g/L yeast extract, 2x trace elements and 50 mg/L kanamycin.
- Onset of the fed-batch feeding was initiated by increase of the DO upon depletion of batch glycerol, thus the second observed DO increased based on carbohydrate depletion.
- Fed-batch feeding was controlled as a typical DO-stat fermentation. Upon each DO increase, addition of feed solution was used equal to 2,9% relative to starting batch volume.
- the feed solution contained 350 g/L glycerol and 10 g/L of Lactose and yeast extract, 50 mg/L kanamycin.
- Fed-batch fermentation was typically performed for 24 hours with either exponential feeding profile or DO stat or until a biomass concentration of at least OD at 600 nm of 50 was reached (see figure 4).
- the fermentation liquid was centrifuged at 4200xg for 20 min at 4°C, the supernatant discarded, and the biomass stored at -80°C until further use.
- the L- serine, L-cysteine and cystine concentrations was measured using a Dionex Ultimate 3000 HPLC (high- performance liquid chromatography) equipped with a CHIROBIOTIC T Chiral (250 x 2.1 mm x 5 pm) column (Sigma-Aldrich, St. Louis, MO, USA) and a Diode Array Detector (DAD-UV).
- the mobile phase comprised of 60% acetonitrile (v/v) and 0.02% (v/v) formic acid in Milli-Q. water.
- the mobile phase was delivered at a rate of 1.0 mL/min.
- the injection volume was 2.5 pL and the standard curve varied from 0.05 to 2 g/L for all compounds.
- L-serine consumption rates did not vary with the L-serine source, with all L-serine being consumed after four hours in both the pure L-serine and L-serine fermentation broth sample.
- L-cysteine and cystine production rates were similar and independent of the L-serine being pure or from fermentation broth (figures 6 and 7).
- Example 5 Downstream purification steps that can be avoided when using serine fermentation broth as a substrate for TrpS.
- the separation of amino acids from the fermentation broth is usually done by centrifugation or filtration followed by a purification steps using chromatographic techniques chosen according to the product properties such as solubility, isoelectric point, and affinity to adsorbent (Hermann, 2003).
- the SuperPro Designer (Intelligen inc) software was used to design an in silica downstream purification process for L-serine.
- the designed process was based on the downstream process currently used to purify the amino acid L-threonine from fermentation broth.
- L-threonine and L-serine are chemically almost identical, with the only difference being that L-threonine has an extra methyl substituent on the R-carbon.
- the downstream process for L-serine purification was expected to be similar to the process used for L-threonine.
- the designed in silica L-serine downstream purification process consists of five main sections: separation, primary purification, concentration, secondary purification, and product recovery. Briefly described the process was as follows: After the serine fermentation has been stopped, the biomass was separated from the fermentation broth by centrifugation. In the primary purification step, the resulting supernatant was loaded onto an ion exchange column, removing the target product from the aqueous feed. After elution, the product solution is pumped into an activated carbon bed to remove any coloured compounds. Next, ammonia was removed, and the resulting product concentrated using a multi-stage evaporator to remove any excess water. The concentrated L-serine liquor was then crystallised, and the crystals recovered and passed through a rotary vacuum filter to generate product of greater than 95% purity (see figure 8).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The present disclosure describes a method for producing cysteine and/or cystine comprising a) providing a fermentation medium comprising serine from of a genetically engineered host cell producing said serine; b) providing one or more sources of sulfur; c) providing one or more pyridoxal 5-phosphate (PLP)-dependent enzymes capable of converting serine into cysteine and/or cystine in the presence of the source of sulfur; d) contacting the serine in the fermentation medium with the pyridoxal 5-phosphate (PLP)- dependent enzyme in the presence of PLP and the source of sulfur under conditions allowing the serine to be converted into cysteine and/or cystine; and optionally e) recovering and/or isolating the cysteine and/or cystine.
Description
Production of cysteine or cystine from serine in fermentation medium
Field
[0001] The present disclosure describes methods for producing L-cysteine and/or L-cystine comprising converting L-serine in a fermentation medium produced by a genetically engineered host cell into L-cysteine and/or L-cystine by contacting the L-serine with a pyridoxal 5-phosphate (PLP)- dependent enzyme in the presence of the source of sulfur. Further described herein are the resulting fermentation media, compositions comprising said medium, microbial cells genetically modified to produce the L-cysteine and/or L-cystine and cell cultures of such genetically modified microbail cells.
Background
[0002] The amino acid L-cysteine is widely used as a pre-cursor in the food, pharmaceutical and personal-care industries, and the estimated annual production of L-cysteine in 2015 was approx. 14000 tons. At present, L-cysteine is primarily produced by acid hydrolysis of feathers and hair (Hashim et al., 2014). This process employs 32 L of concentrated HCI per kg of L-cysteine and is therefore not only expensive, but also creates a lot of acidic wastewater (Hashim et al., 2014). Furthermore, the end-product is known to contain impurities of animal and even human origin known to cause allergies. As an alternative production method, companies such as Wacker Chemie AG, use a microbial fermentation process, which unfortunately produces low yields (Reutter-Maier et al., 2014). Therefore, identification of new L-cysteine production methods that are economically feasible and sustainable is highly desirable.
[0003] Previous research has shown that L-cysteine can be produced via an enzymatic reaction using the enzyme tryptophan synthase (TrpS) (Ishiwata et al., 1989). TrpS is a pyridoxal 5-phosphate (PLP)- dependent enzyme found in many domains of life as an appa heterodimeric complex. Physiologically, it is known to catalyze the synthesis of tryptophan and glyceraldehyde-3-phosphate from L-serine and indole 3-glycerol phosphate (Raboni et al., 2009). The a-subunit of tryptophan synthase converts indole-3-glycerol phosphate to indole and D-glyceraldehyde-3-phosphate. The indole is transported to the p-subunit via a substrate tunnel, where it reacts with L-serine in the presence of the cofactor PLP, to generate tryptophan and water (Raboni et al., 2009).
[0004] E. coli strains capable of producing L-serine titers >50 g/L via fermentation have previously bee described for example in US20210095245 or US10513682.
Summary
[0005] Over this background art the present inventors have found and/or confirmed that the betasubunit of TrpS is highly promiscuous and accept an array of different nucleophilic substrates and that amongst the nucleophiles accepted are the hydrogen sulfide ion which, in the presence of TrpS, can react with L-serine to produce L-cysteine. Using this approach, for example TrpS form E. coli can be shown to effectively produce L-cysteine from purified L-serine in the presence of sodium hydrogen sulfide and the PLP enzyme co-factor. These findings suggest that TrpS can produce L-cysteine efficiently, but the relatively high cost of L-serine has prohibited development of commercially attractive production of L-cysteine from L-serine and sodium hydrogen sulfide.
[0006] While production of L-serine via fermentation reduces the production cost, one of the primary cost contributors to L-serine production is the extensive downstream processing required to obtain pure L-serine (see eg. D'Este et al., 2018; Hermann, 2003; Kumar et al., 2014). To resolve the drawbacks of using the technically complicated and therefore expensive process in the art for making purified L-serine, the present inventors have found a method using impure L-serine from a fermentation directly as a substrate for TrpS in the making of cysteine and/or cystine.
[0007] These results are indeed unexpected, as production of cysteine from L-serine in fermentation broth or even crude serine preparations has not previously been demonstrated, and because the presence of inhibitors in the broth were expected to inhibit or block the reaction. Moreover, the methods for cysteine biocatalysis described herein were, at the onset of developing the method, presumed to be challenging, because it required sulfur containing compounds, such as hydrogen sulfide, because such compounds are strong bases, and highly ionic molecules, which are known to considerably affect and impede enzyme stability and activity (Yang, 2009). In addition, fermentation broths of high cell density of for example E. coli cultures are known to comprise many inhibiting compounds that affects and impede enzyme stability and activity. Therefore it was unexpected to find that fermentation broths comprising L-serine produced by fermenting a microorganism genetically modified to produce L-serine, said broths having an optical density (OD 600 nm) of up to and above 40 and a serine concentration of up to and above >50 g/L, could be used for making enzymatically converted L-cysteine and/or L-cystine and that the method was, in efficiency, comparable to using pure L-serine as a substrate. In particular it was unexpected that TrpS catalysed the conversion of L- serine in the fermentation media at a rate comparable to the conversion of pure L-serine.
[0008] This suggests that L-serine fermentation broths can advantageously be used directly as a substrate for L-cysteine/L-cystine production, without any prior technically complicated, expensive and yield reducing purification steps.
[0009] Accordingly, in a first aspect the disclosure describes a method for producing L-cysteine and/or
L-cystine comprising: a) providing a fermentation medium comprising serine from of a genetically engineered host cell producing said serine; b) providing one or more sources of sulfur; c) providing one or more pyridoxal 5-phosphate (PLP)-dependent enzymes capable of converting serine into cysteine and/or cystine in the presence of the source of sulfur; d) contacting the serine in the fermentation medium with the pyridoxal 5-phosphate (PLP)- dependent enzyme in the presence of PLP and the source of sulfur under conditions allowing the serine to be converted into cysteine and/or cystine; and optionally e) recovering and/or isolating the cysteine and/or cystine
[0010] In a further aspect the disclosure describes a fermentation medium comprising L-cysteine and/or L-cystine, obtainable from the method as described herein.
[0011] In a further aspect the disclosure describes a composition comprising the fermentation medium described herein and one or more agents, additives and/or excipients.
[0012] In a further aspect the disclosure describes a microbial host cell genetically modified to produce L-cysteine and/or L-cystine, wherein the host cell expresses a heterologous gene encoding a pyridoxal 5-phosphate (PLP)-dependent enzyme and comprises an operative biosynthetic pathway capable of producing L-serine, said pathway comprising one or more pathway polypeptides selected from: a) glucokinase (glk) phosphorylating glucose to glucose-6-phosphate; b) phosphoglucose isomerase (pgi) isomerizing glucose-6-phosphate to fructose-6-phosphate; c) phosphofructokinase 2(pfkB) phosphorylating fructose-6-phosphate to fructose-1.6- bisphosphate; d) fructose-bisphosphate aldolase class 1 (fbaB) or fructose-bisphosphate aldolase class 2 (fbaA) splitting fructose 1,6-bisphosphate into dihydroxyacetone phosphate and glyceraldehyde 3- phosphate; e) triosephosphate isomerase (tpiA) converting dihydroxyacetone phosphate to D-glyceraldehyde- 3-phosphate; f) glyceraldehyde-3-phosphate dehydrogenase A (gapA) oxidatively phosphorylating D- glyceraldehyde 3-phosphate (G3P) to 1,3-bisphosphoglycerate (BPG) using the cofactor NAD; g) glyceraldehyde-3-phosphate dehydrogenase (gapC) converting D-glyceraldehyde 3-phosphate into 1,3-bisphosphoglyceric acid; h) phosphoglycerate kinase (pgk) dephosphorylating 1,3-bisphosphoglyceric acid to generate 3- phospho-D-glycerate;
i) D-3-phosphoglycerate dehydrogenase (serA) oxidizing 3-phospho-D-glycerate to 3- phosphohydroxypyruvate; j) phosphoserine aminotransferase (serC) converting 3-phosphohydroxypyruvate to phosphoserine; or k) phosphoserine phosphatase (serB) dephosphorylating phosphoserine to L-serine.
Brief description of drawings and figures
Figure 1 shows a reaction scheme for the R-subunit of tryptophan synthase, (top) The natural reaction catalysed by the R-subunit of tryptophan synthase where the indole is transported to the p-subunit via a substrate tunnel, where it reacts with L-serine in the presence of the cofactor PLP, to generate tryptophan and water. (Bottom) The reaction of the present disclosure for producing L-cysteine from L-serine and sodium hydrogen sulfide in the presence of PLP. Upon oxidation, cysteine may subsequently be converted to its dimeric form cystine.
Figure 2 shows the production of L-serine by fermentation by a strain of E. coli. (top) E. coli growth as a function of time for a representative serine producing fermentation. (Bottom) Serine titers as a function of time for a representative serine producing fermentation.
Figure 3 shows the expression of E. coli tryptophan synthase. (Top) Plasmid map of the plasmid used to express the trpS complex (trpA and trpB) from E. coli. (Bottom) SDS-PAGE analysis of TrpS expression. Distinct bands of overexpressed proteins are visible at approx. 30 and 43 kDa, which correlates well with the expected mass of nHis-trpA (29.8 kDa) and trpB (43 kDa), respectively.
Figure 4 shows the fermentation of Cys_39 producing TrpS. (Top) The feed volume scheme resulting from a standard DO-sat controlled fermentation of Cys_39 to generate biomass for cysteine production. (Bottom) Cys_39 growth as a function of time for a representative Cys_39 DO-stat controlled fermentation.
Figure 5 to 7 shows the conversion of L-serine to L-cysteine and L-cystine using pure L-serine and L- serine fermentation broth as substrates. Results from pure serine are shown in gray, and results from the serine fermentation broth are shown in black.
Figure 8 shows a blok flow diagram of the designed serine downstream purification process. The serine broth used as a TrpS substrate in the examples is also indicated in the diagram.
Figure 9 shows the metabolic pathway from glucose to cysteine.
Incorporation by reference
[0013] All publications, patents, and patent applications referred to herein are incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. In the event of a conflict between a term herein and a term in an incorporated reference, the term herein prevails and controls.
Details
Definitions
[0014] Any EC numbers used herein refers to Enzyme Nomenclature 1992 from NC-IUBMB, Academic Press, San Diego, California, including 30 supplements 1-5 published in Eur. J. Bio-chem. 1994, 223, 1- 5; Eur. J. Biochem. 1995, 232, 1-6; Eur. J. Biochem. 1996, 237, 1-5; Eur. J. Biochem. 1997, 250, 1-6; and Eur. J. Biochem. 1999, 264, 610-650; respectively. The nomenclature is regularly supplemented and updated; see e.g. http://enzyme.expasy.org/. The term "PEP" as used herein refers to phosphoenol pyruvate.
[0015] The term "pyridoxal 5-phosphate (PLP)-dependent enzymes" as used herein refers to any PLP dependent enzyme catalyzing the reaction of L-serine and sulfur containing reactant into L-cysteine.
[0016] The term "glucokinase or glk" as used herein refers to an enzyme catalyzing the reaction of phosphorylating glucose into glucose-6-phosphate.
[0017] The term "phosphoglucose isomerase or pgi" as used herein refers to an enzyme catalyzing the reaction of isomerizing glucose-6-phosphate into fructose-6-phosphate
[0018] The term "phosphofructokinase or pfkB" as used herein refers to an enzyme catalyzing the reaction of phosphorylating fructose-6-phosphate into fructose-1.6-bisphosphate.
[0019] The term "fructose-bisphosphate aldolase calss 1 or 2 or fbaB or fbaA" as used herein refers to enzymes splitting fructose 1,6-bisphosphate into dihydroxyacetone phosphate and glyceraldehyde 3-phosphate.
[0020] The term "triosephosphate isomerase or tpiA" as used herein refers to an enzyme catalyzing the reaction of converting dihydroxyacetone phosphate into D-glyceraldehyde-3-phosphate.
[0021] The term "glyceraldehyde-3-phosphate dehydrogenase A or gapA" as used herein refers to an enzyme catalyzing the reaction of oxidatively phosphorylating D-glyceraldehyde 3-phosphate (G3P) into 1,3-bisphosphoglycerate (BPG) using the cofactor NAD.
[0022] The term "glyceraldehyde-3-phosphate dehydrogenase or gapC" as used herein refers to an
enzyme catalyzing the reaction of converting D-glyceraldehyde 3-phosphate into 1,3- bisphosphoglyceric acid.
[0023] The term "phosphoglycerate kinase or pgk" as used herein refers to an enzyme catalyzing the reaction of dephosphorylating 1,3-bisphosphoglyceric acid into generate 3-phospho-D-glycerate.
[0024] The term "D-3-phosphoglycerate dehydrogenase or serA" as used herein refers to an enzyme catalyzing the reaction of oxidizing 3-phospho-D-glycerate into 3-phosphohydroxypyruvate.
[0025] The term "phosphoserine aminotransferase or serC" as used herein refers to an enzyme catalyzing the reaction of converting 3-phosphohydroxypyruvate into phosphoserine.
[0026] The term "phosphoserine phosphatase (serB)" as used herein refers to an enzyme catalyzing the reaction of dephosphorylating phosphoserine into L-serine.
[0027] The terms "heterologous" or "recombinant" or "genetically modified" and their grammatical equivalents as used herein interchangeably refers to entities "derived from a different species or cell". For example, a heterologous or recombinant polynucleotide gene is a gene in a host cell not naturally containing that gene, i.e. the gene is from a different species or cell type than the host cell. The terms as used herein about microbial host cells refers to microbial host cells comprising and expressing heterologous or recombinant polynucleotide genes.
[0028] The term "biosynthetic pathway" as used herein is intended to mean two or more enzymes acting sequentially in a live cell to convert chemical substrate(s) into chemical product(s). Enzymes are characterized by having catalytic activity, which can change the chemical structure of the substrate(s). An enzyme may have more than one substrate and produce more than one product. The enzyme may also depend on cofactors, which can be inorganic chemical compounds or organic compounds such as proteins for example enzymes (co-enzymes).
[0029] The term "operative biosynthetic pathway" refers to a metabolic pathway that occurs in a live recombinant host, as described herein.
[0030] The term "in vivo", as used herein refers to within a living cell or organism, including, for example animal, a plant or a microorganism.
[0031] The term "in vitro", as used herein refers to outside a living cell or organism, including, without limitation, for example, in a microwell plate, a tube, a flask, a beaker, a tank, a reactor and the like.
[0032] The term "substrate" or "precursor", as used herein refers to any compound that can be converted into a different compound. For clarity, substrates and/or precursors include both compounds generated in situ by a enzymatic reaction in a cell or exogenously provided compounds, such as exogenously provided organic molecules which the host cell can metabolize into a desired compound.
[0033] Term "endogenous" or "native" as used herein refers to a gene or a polypepetide in a host cell
which originates from the same host cell.
[0034] The term "deletion" as used herein refers to manipulation of a gene so that it is no longer expressed in a host cell.
[0035] The term "disruption" as used herein refers to manipulation of a gene or any of the machinery participating in the expression the gene, so that it is no longer expressed in a host cell.
[0036] The term "attenuation" as used herein refers to manipulation of a gene or any of the machinery participating in the expression the gene, so that it the expression of the gene is reduced as compared to expression without the manipulation.
[0037] The terms "substantially" or "approximately" or "about", as used herein refers to a reasonable deviation around a value or parameter such that the value or parameter is not significantly changed. These terms of deviation from a value should be construed as including a deviation of the value where the deviation would not negate the meaning of the value deviated from. For example, in relation to a reference numerical value the terms of degree can include a range of values plus or minus 10% from that value. For example, deviation from a value can include a specified value plus or minus a certain percentage from that value, such as plus or minus 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1% from the specified value.
[0038] The term "and/or" as used herein is intended to represent an inclusive "or". The wording X and/or Y is meant to mean both X or Y and X and Y. Further the wording X, Y and/or Z is intended to mean X, Y and Z alone or any combination of X, Y, and Z.
[0039] The term "isolated" as used herein about a compound, refers to any compound, which by means of human intervention, has been put in a form or environment that differs from the form or environment in which it is found in nature. Isolated compounds include but is no limited to compounds of the disclosure for which the ratio of the compounds relative to other constituents with which they are associated in nature is increased or decreased. In an important embodiment the amount of compound is increased relative to other constituents with which the compound is associated in nature. In an embodiment the compound of the disclosure may be isolated into a pure or substantially pure form. In this context a substantially pure compound means that the compound is separated from other extraneous or unwanted material present from the onset of producing the compound or generated in the manufacturing process. Such a substantially pure compound preparation contains less than 10%, such as less than 8%, such as less than 6%, such as less than 5%, such as less than 4%, such as less than 3%, such as less than 2%, such as less than 1 %, such as less than 0.5% by weight of other extraneous or unwanted material usually associated with the compound when expressed natively or recombinantly. In an embodiment the isolated compound is at least 90% pure, such as at least 91% pure, such as at least 92% pure, such as at least 93% pure, such as at least 94% pure, such
as at least 95% pure, such as at least 96% pure, such as at least 97% pure, such as at least 98% pure, such as at least 99% pure, such as at least 99.5% pure, such as 100 % pure by weight.
[0040] The term "% identity" is used herein about the relatedness between two amino acid sequences or between two nucleotide sequences. The term "% identity" as used herein about amino acid sequences refers to the degree of identity in percent between two amino acid sequences obtained when using the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, J. Mol. Biol. 48: 443- 453) as implemented in the Needle program of the EMBOSS package (EMBOSS: The European Molecular Biology Open Software Suite, Rice et al., 2000, Trends Genet. 16: 276-277), preferably version 5.0.0 or later. The parameters used are gap open penalty of 10, gap extension penalty of 0.5, and the EBLOSUM62 (EMBOSS version of BLOSUM62) substitution matrix. The output of Needle labeled "longest identity" (obtained using the -nobrief option) is used as the percent identity and is calculated as follows: identical amino acid residues - x 100 Length of alignment — total number of gaps in alignment
The term "% identity" as used herein about nucleotide sequences refers to the degree of identity in percent between two nucleotide sequences obtained when using the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, supra) as implemented in the Needle program of the EMBOSS package (EMBOSS: The European Molecular Biology Open Software Suite, Rice et al., 2000, supra), preferably version 5.0.0 or later. The parameters used are gap open penalty of 10, gap extension penalty of 0.5, and the EDNAFULL (EMBOSS version of NCBI NUC4.4) substitution matrix. The output of Needle labeled "longest identity" (obtained using the -nobrief option) is used as the percent identity and is calculated as follows: identical deoxyribonucleotides - - - x 100 Length of alignment — total number of gaps in alignment
The protein sequences of the present disclosure can further be used as a "query sequence" to perform a search against sequence databases, for example to identify other family members or related sequences. Such searches can be performed using the BLAST programs. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov). BLASTP is used for amino acid sequences and BLASTN for nucleotide sequences. The BLAST program uses as defaults:
Cost to open gap: default= 5 for nucleotides/ 11 for proteins
Cost to extend gap: default = 2 for nucleotides/ 1 for proteins
Penalty for nucleotide mismatch: default = -3
Reward for nucleotide match: default= 1
Expect value: default = 10
Wordsize: default = 11 for nucleotides/ 28 for megablast/ 3 for proteins.
Furthermore, the degree of local identity between the amino acid sequence query or nucleic acid sequence query and the retrieved homologous sequences is determined by the BLAST program. However only those sequence segments are compared that give a match above a certain threshold. Accordingly, the program calculates the identity only for these matching segments. Therefore, the identity calculated in this way is referred to as local identity.
[0041] The term "expression" includes any step involved in the production of a polypeptide including, but not limited to, transcription, post-transcriptional modification, translation, post- translational modification, and secretion.
[0042] The term "expression vector" refers to a DNA molecule, either single- or double stranded, either linear or circular, which comprises a polynucleotide encoding a polypeptide and is operably linked to control sequences that provide for its expression. Expression vectors include expression cassettes for the integration of genes into a host cell as well as plasmids and/or chromosomes comprising such genes.
[0043] The term "host cell" refers to any cell type that is susceptible to transformation, transfection, transduction, or the like with a nucleic acid construct or expression vector comprising a polynucleotide of the present disclosure. Host cell encompasses any progeny of a parent cell that is not identical to the parent cell due to mutations that occur during replication.
[0044] The term "polynucleotide construct" or "nucleic acid construct" refers to a polynucleotide, either single- or double stranded, which is separated from its naturally occurring environment and/or is modified to contain segments of nucleic acids in a manner that would not otherwise exist in nature or which is synthetic, and which comprises a polynucleotide encoding a polypeptide and one or more control sequences.
[0045] The term "operably linked" refers to a configuration in which a control sequence is placed at an appropriate position relative to the coding polynucleotide such that the control sequence directs expression of the coding polynucleotide.
[0046] The terms "nucleotide sequence and "polynucleotide" are used herein interchangeably.
[0047] The term "comprise" and "include" as used throughout the specification and the
accompanying items as well as variations such as "comprises", "comprising", "includes" and "including" are to be interpreted inclusively. These words are intended to convey the possible inclusion of other elements or integers not specifically recited, where the context allows.
[0048] The articles "a" and "an" are used herein refers to one or to more than one (i.e. to one or at least one) of the grammatical object of the article. By way of example, "an element" may mean one element or more than one element.
[0049] Terms like "preferably", "commonly", "particularly", and "typically" are not utilized herein to limit the scope of the itemed disclosure or to imply that certain features are critical, essential, or even important to the structure or function of the itemed disclosure. Rather, these terms are merely intended to highlight alternative or additional features that can or cannot be utilized in a particular embodiment of the present disclosure.
[0050] The term "cell culture" as used herein refers to a culture medium comprising a plurality of host cells of the disclosure. A cell culture may comprise a single strain of host cells or may comprise two or more distinct host cell strains. The culture medium may be any medium that may comprise a recombinant host, e.g., a liquid medium (i.e., a culture broth) or a semi-solid medium, and may comprise additional components, e.g., a carbon source such as dextrose, sucrose, glycerol, or acetate; a nitrogen source such as ammonium sulfate, urea, or amino acids; a phosphate source; vitamins; trace elements; salts; amino acids; nucleobases; and yeast extract.
[0051] The term "fermentation medium" as used herein refers to any medium in which a genetically modified host is producing or has produced L-serine. A fermentation medium may contain solid cellular material (broths) or may be partially or wholly free of solid cellular material.
[0052] The term "sources of sulfur" as used herein refers to any compound comprising sulfur in a form which the pyridoxal 5-phosphate (PLP)-dependent enzyme can covalently bind to serine to from cysteine.
Method for producing cysteine and/or cystine comprising
[0053] As described, supra, the first aspect of the present disclosure concerns a method for producing cysteine and/or cystine comprising a) providing a fermentation medium and/or broth comprising serine from of a genetically engineered host cell producing said serine, and optionally comprising metabolites and/or cells and/or cell debris from the serine producing host cell; b) providing one or more sources of sulfur; c) providing one or more pyridoxal 5-phosphate (PLP)-dependent enzymes; d) contacting the serine in the fermentation medium with the pyridoxal 5-phosphate (PLP)-
dependent enzyme in the presence of the source of sulfur under conditions allowing the serine to be converted into cysteine and/or cystine; and optionally e) recovering and/or isolating the cysteine and/or cystine.
[0054] In some aspects, the method for producing cysteine and/or cystine is provided comprising a) providing a fermentation medium comprising serine from of a genetically engineered host cell producing said serine; b) providing one or more sulfur sources which are NaSH; NajS; and/or H2S c) providing a pyridoxal 5-phosphate (PLP)-dependent enzyme TrpS comprising i) an enzyme subunit having an amino acid sequence comprised in SEQ ID NO: 13 (trpB) and ii) an enzyme subunit having an amino acid sequence comprised in SEQ. ID NO: 14 (trpA), wherein the subunits, alone and together, are capable of converting serine into cysteine and/or cystine in the presence of the one or more sulfur sources; d) contacting the serine in the fermentation medium with the pyridoxal 5-phosphate (PLP)- dependent enzyme TrpS in the presence of PLP and the one or more sulfur sources under conditions allowing the serine to be converted into cysteine and/or cystine; and e) optionally recovering and/or isolating the cysteine and/or cystine.
[0055] In the said method it is particularly attractive to produce L-cysteine and/or L-cystine. Cysteine is usually in equilibrium with cystine through oxidation, but in further embodiment the method can also comprise steps with the aim of converting the monomeric cysteine to the dimeric cystine or shifting the equilibriums in either direction depending on which of cysteine or cystine that are most desirable.
[0056] In some preferred embodiements the fermentation medium used in the methods described herein is a broth which comprises components of the host cells and/or components produced by the host cells from the extracellular or intracellular matrix or both, components produced by the host cells includes particularly metabolites of the host cell production of serine such as those selected from glucose-6-phosphate, fructose-l,6-phosphate, glyceraldehyde-3-phosphate, dihydroxyacetone phosphate, 1,3-diphosphoglycerate, 3-phosphoglycerate, 3-phosphopyrovate, and/or 3- phosphoserine. In additional or alternative embodiments such components of the fermentation mediums can also comprise by one or more components selected from: a) a carbon source, optionally selected from glycerol; carbohydrates (such as monosaccharides and/or disaccharides; complex sources (such as molasses, fats and oils, and/or starch biomass; b) a nitrogen source, optionally selected from ammonium compounds, nitrates, Urea and/or Amino acids such as alanine arginine, Leucine, and/or D,L-aspartate; c) a phosphate source, optionally selected from potassium phosphate;
d) a sulfate source, optionally selected from ammonium sulfate and/or magnesium sulfate; e) trace elements, optionally selected from Fe, Zn, Cu, Mn, Mo, Co, and/or Ni.
[0057] In further embodiments the fermentation medium comprises ammonium ions, optionally between 0,1 g/L to 20 g/L, optionally between 0,5 g/L to 15 g/L, optionally between 1 g/L to 10 g/L, optionally between 2 g/L to 5 g/L of ammonium ions.
[0058] In further embodiments the fermentation medium comprises phosphate ions, optionally between 0,01 g/L to 10 g/L, optionally between 0,02 g/L to 5 g/L, optionally between 0,05 g/L to 2 g/L of phosphate ions.
[0059] In further embodiments the fermentation medium comprises proteins, DNA and RNA liberated by the host cells.
[0060] In further embodiments the fermentation medium comprises live cells and/or cell debris, optionally between 0,1 %wt to 75 %wt, optionally between 0,5 %wt to 50 %wt, optionally between 1 %wt to 40 %wt, optionally between 2 %wt to 35 %wt, optionally between 3 %wt to 30 %wt, optionally between 5 %wt to 25 %wt, optionally between 10 %wt to 20 %wt.
[0061] In further embodiments the fermentation medium comprises N-acetyl serine, optionally between 0,05 g/L to 20 g/L, optionally between 0,1 g/L to 10 g/L, optionally between 0,5 g/L to 2 g/L of N-acetyl serine.
[0062] The fermentation medium comprises pyridoxal 5-phosphate (PLP) cofactor, suitable in amounts of at least 0,01 pM, such as at least 0,05 pM, such as at least 0,1 pM, such as at least 0,5 pM, such as at least 1 pM, such as at least 5 pM, such as at least 10 pM, such as at least 50 pM, such as at least 100 pM, such as at least 250 pM, such as at least 500 pM, such as at least 1 mM but suitably not higher than 10 mM.
[0063] The fermentation medium comprises serine, in amounts which suitably priorto any conversion of serine into cysteine is at least 10 g/L serine, such as at least 20 g/L, such as at least 30 g/L, such as at least 40 g/L, such as at least 50 g/L, such as at least 60 g/L, such as at least 70 g/L, such as at least 70 g/L, such as at least 80 g/L, such as at least 90 g/L, but suitably below 500 g/L, such as below 250 g/L, such as below 200 g/L, such as below 150 g/L, such as below 125 g/L, such as below 100 g/L. A particular amount is between 50 to 100 g/L of serine which is obtainable in high yield fermentations. In some embodiments during and after the conversion of serine to cysteine, the concentration of serine in the fermentation medium is lowered, while in other embodiments where a host cell continuously produces new serine, concentrations of serine may reach a stady state within the aforementions ranges. An additional or alternative embodiments the fermentation providing the fermentation medium is advantageously progressed to a stage where the optical density (OD) at 600 nm is at least 1, such as at least 2, such as at least 4, such as at least 6, such as at least 8, such as at
least 10, such as at least 15, such as at least 20, inducating the concentration of cells or cellular debris is so high as to also provide for a high concentration of serine.
[0064] The the one or more sources of sulfur can be any compound comprising sufur and which the pyridoxal 5-phosphate (PLP)-dependent enzyme is capable of using for covalendly binding hydrogen sulfide (-SH) to serine. Such sulfur compounds include any compound which in solution can generate such as H2S, S2-, and/or NaHS. In a particular embodiment the one or more sources of sulfur comprises hydrogen sulfide. Additionally or alternatively, the source of sulfur comprises a basic compound, such as a strongly basic compound. Additionally or alternatively, the source of sulfur comprises an acidic compound, such as a strongly acidic compound. In some embodiments it is desired to maintain a certain minimum level of the the sulfur source during at least the major period of conversion of serine to cysteine. In particular it is desired to maintain a concentration of the source of sulfur of at least 0,1 % wt, such as least 0,5 % wt, such as least 1 % wt, such as least 2 % wt, such as least 4 % wt, such as least 6 % wt, such as least 8 % wt, such as least 10 % wt, but suitably less than 15 % wt.
[0065] The pyridoxal 5-phosphate (PLP)-dependent enzyme used the method described can be derived from a bacterium, such as a strain of the genus Eschericia, particularly of the species Eschericia coli. In some embodiemnts the pyridoxal 5-phosphate (PLP)-dependent enzyme is selected from lyases (EC 4.-.-.-), carbon oxygen lyases (EC 4.2.-.-), and/or hydro-lyases (EC 4.2.1.-). In other additional or alternative embodiments the pyridoxal 5-phosphate (PLP)-dependent enzyme comprises a fold type II configuration such as described in (Percudani 2009, B6 database). In some embodiments the pyridoxal 5-phosphate (PLP)-dependent enzyme is a Tryptophan synthase (TrpS), especially an E. coli TrpS, optionally comprising an amino acid sequence which has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to one or more of SEQ ID NO: 13 (trpB), 14 (trpA), 15 (trpB) or 16 (trpA).
[0066] [0060] [0061] In further additional or alternative embodiments, the pyridoxal 5-phosphate (PLP)-dependent enzyme comprises one or more mutations outside the PLP binding site and/or outside the substrate binding site. The PLP binding site of the pyridoxal 5-phosphate (PLP)-dependent enzyme suitably comprises one or more amino acid moieties corresponding to position H86, K87, Q114, T190, C230, G232, G233, G234, S235, N236, A237, G303, E350, S377, or G378 of SEQ. ID NO: 15 or 16, while the substrate binding site of the pyridoxal 5-phosphate (PLP)-dependent enzyme suitably comprises one or more amino acid moieties corresponding to position N305, A112, Gill, T110, Q114, H115, G113, or E109 of SEQ ID NO: 15 or 16.
[0067] In further additional or alternative embodiments, the pyridoxal 5-phosphate (PLP)-dependent enzyme comprises one or more mutations selected from D47S and L81V in the corresponding amino
acid sequence of SEQ. ID NO: 15 or 16 or conservative substitutions thereof.
[0068] The method produces cysteine/cystine with high efficiency and in some embodiments at least 50%, such as at least 75%, such as at least 85%, such as at least 90%, such as at least 95%, such as at least 98% of the serine in the fermentation medium is converted to cysteine and/or cystine.
[0069] The method can further comprise steps for generating serine from one or more precursors including one or more steps selected from a) Phosphorylation of glucose by Glucokinase (glk) to generate glucose-6-phosphate; b) Isomerisation of glucose-6-phosphate by phosphoglucose isomerase (pgi) to generate fructose- 6-phosphate; c) Phosphorylation of fructose-6-phosphate by phosphofructokinase 2(pfkB) to generate fructose- 1.6-bisphosphate; d) Splitting of fructose 1,6-bisphosphate by fructose-bisphosphate aldolase class 1 (fbaB) or fructose-bisphosphate aldolase class 2 (fbaA) into dihydroxyacetone phosphate and glyceraldehyde 3-phosphate; e) Conversion of dihydroxyacetone phosphate by triosephosphate isomerase (tpiA) to D- glyceraldehyde-3-phosphate; f) oxidative phosphorylation of D-glyceraldehyde 3-phosphate (G3P) by glyceraldehyde-3- phosphate dehydrogenase A (gapA) to 1,3-bisphosphoglycerate (BPG) using the cofactor NAD; g) conversion of D-glyceraldehyde 3-phosphate by glyceraldehyde-3-phosphate dehydrogenase (gapC) into 1,3-bisphosphoglyceric acid; h) Dephosphorylation of 1,3-bisphosphoglyceric acid by phosphoglycerate kinase (pgk) to generate 3-phospho-D-glycerate; i) oxidation of 3-phospho-D-glycerate by D-3-phosphoglycerate dehydrogenase (serA) to 3- phosphohydroxypyruvate; j) conversion of 3-phosphohydroxypyruvate by phosphoserine aminotransferase (serC) to phosphoserine; k) dephosphorylation of phosphoserine by phosphoserine phosphatase (serB) to serine; and/or l) conversion of formaldehyde and glycine by serine hydroxymethyl transferase (glyA) to serine.
[0070] In a special embodiment the method comprises: a) oxidation of 3-phospho-D-glycerate by D-3-phosphoglycerate dehydrogenase (serA) to 3- phosphohydroxypyruvate; b) conversion of 3-phosphohydroxypyruvate by phosphoserine aminotransferase (serC) to phosphoserine; or c) dephosphorylation of phosphoserine by phosphoserine phosphatase (serB) to serine.
[0071] In the method described herein in some embodiments the glucokinase (glk) has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the Glucokinase comprised in SEQ ID NO: 1. In other embodiments the phosphoglucose isomerase (pgi) has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the phosphoglucose isomerase (pgi) comprised in SEQ. ID NO: 2. In other embodiments the phosphofructokinase 2 (pfkB) has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the phosphofructokinase 2 (pfkB) comprised in SEQ ID NO: 3. In other embodiments the fructose-bisphosphate aldolase class 1 (fbaB) has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the fructose-bisphosphate aldolase comprised in SEQ ID NO: 4. In other embodiments the fructose-bisphosphate aldolase class 2 (fbaA) has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the fructose-bisphosphate aldolase comprised in SEQ ID NO: 5. In other embodiments the triosephosphate isomerase (tpiA) has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the triosephosphate isomerase comprised in SEQ ID NO: 6. In other embodiments the glyceraldehyde-3-phosphate dehydrogenase A (gapA) has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the glyceraldehyde-3-phosphate dehydrogenase A comprised in SEQ ID NO: 7. In other embodiments the glyceraldehyde-3-phosphate dehydrogenase (gapC) has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the glyceraldehyde-3-phosphate dehydrogenase comprised in SEQ ID NO: 8. In other embodiments the phosphoglycerate kinase (pgk) has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the phosphoglycerate kinase comprised in SEQ ID NO: 9. In other embodiments the D-3- phosphoglycerate dehydrogenase (serA) has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the D-3-phosphoglycerate dehydrogenase comprised in a
sequence selected from the group consisting of: SEQ ID NO: 10, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, and SEQ ID NO: 47. In one embodiment, the D-3-phosphoglycerate dehydrogenase (serA) has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the D-3- phosphoglycerate dehydrogenase comprised in SEQ ID NO: 10. In other embodiments the phosphoserine aminotransferase (serC) has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the phosphoserine aminotransferase comprised in SEQ ID NO: 11. In other embodiments the phosphoserine phosphatase (serB) has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the phosphoserine phosphatase comprised in SEQ ID NO: 12. In the method described herein in some embodiments the serine hydroxymethyl transferase (glyA) has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the serine hydroxymethyl transferase comprised in SEQ ID NO: 26.
[0072] In further optimizing the method described herein the pH in the fermentation medium during conversion of serine to cysteine is suitably kept from about 6 to about 10, such as from about 7 to about 9, allowing the pH to fluctuate around these end points with 0,1 pH.
[0073] In further optimizing the method described herein the temperature in the fermentation medium is kept from about 25°C to about 60°C, such as from about about 30°C to about 50°C, such as from about about 35°C to about 40°C, such as about 37°C allowing the temperature to fluctuate around these end points with 1 °C.
[0074] The recovery and/or isolation of cysteine and/or cystine as described herein suitable comprise one or more steps selected from: a) Separation of any biomass from the fermentation medium b) contacting the fermentation medium with one or more adsorbent resins to obtain at least a portion of the produced cysteine and/or cystine; c) contacting the fermentation medium with one or more ion exchange or reversed-phase chromatography columns in order to obtain at least a portion of the cysteine and/or cystine; d) extracting the cysteine and/or cystine from the fermentation medium; and
e) precipitating the cysteine and/or cystine from the fermentation medium by crystallization or evaporating the solvent of the liquid phase; and optionally isolating cysteine and/or cystine by filtration or gravity separation; thereby recovering and/or isolating the cysteine and/or cystine.
Fermentation mediums and compositions
[0075] As described, supra, a further aspect of the present disclosure concerns a fermentation medium comprising cysteine and/or cystine, obtainable from the method described herein. Apart from cysteine/cystine the fermentation medium can include one or more component selected from unspent PLP, unspent sulfur source; unspent serine, pyridoxal 5-phosphate (PLP)-dependent enzyme; as well as metabolites of the host cell production of serine such as those selected from glucose-6- phosphate, fructose-l,6-phosphate, glyceraldehyde-3-phosphate, dihydroxyacetone phosphate, 1,3- diphosphoglycerate, 3-phosphoglycerate, 3-phosphopyrovate, and/or 3-phosphoserine. The fermentation medium can also include unspent components selected from: f) a carbon source, optionally selected from glycerol; carbohydrates (such as monosaccharides and/or disaccharides; complex sources (such as molasses, fats and oils, and/or starch biomass; g) a nitrogen source, optionally selected from ammonium compounds, nitrates, Urea and/or Amino acids such as alanine arginine, Leucine, and/or D,L-aspartate; h) a phosphate source, optionally selected from potassium phosphate; i) a sulfate source, optionally selected from ammonium sulfate and/or magnesium sulfate; or j) trace elements, optionally selected from Fe, Zn, Cu, Mn, Mo, Co, and/or Ni;
[0076] In the fermentation after conversion of serine to cysteine/cystine the concentration of cysteine and/or cystine at least 0,1 % by weight, such as at least 0,5 % by weight, such as at least 1 % by weight, such as at least 5 % by weight, such as at least 10 % by weight, such as at least 15 % by weight.
[0077] As described, supra, a further aspect of the present disclosure concerns a composition comprising the fermentation medium described herein and one or more agents, additives and/or excipients. In such as composition the fermentation medium is suitably further processed into a dry solid form or a stabilized liquid form, but removing water or other solvents
[0078] In some embodiments, a fermentation compound is a constituent of a fermentation medium or a compound produced by a fermentation process. In some embodiments, non-limiting exemplary fermentation compounds are selected from glucose-6-phosphate, fructose-l,6-phosphate, glyceraldehyde-3-phosphate, dihydroxyacetone phosphate, 1,3-diphosphoglycerate, 3- phosphoglycerate, 3-phosphopyrovate, 3-phosphoserine, glycerol, monosaccharides, disaccharides,
ammonium compounds, nitrates, urea, alanine, arginine, leucine, D-aspartate, potassium phosphate, ammonium sulfate, magnesium sulfate, Fe, Zn, Cu, Mn, Mo, Co, and/or Ni.
Genetically modified host cells
[0079] As described, supra, a further aspect of the present disclosure concerns a microbial host cell genetically modified to produce cysteine and/or cystine, wherein the host cell expresses a heterologous gene encoding a pyridoxal 5-phosphate (PLP)-dependent enzyme and comprises an operative biosynthetic pathway capable of producing serine, said pathway comprising one or more pathway polypeptides selected from: a) glucokinase (glk) phosphorylating glucose to glucose-6-phosphate; b) phosphoglucose isomerase (pgi) isomerizing glucose-6-phosphate to fructose-6-phosphate; c) phosphofructokinase 2(pfkB) phosphorylating fructose-6-phosphate to fructose-1.6- bisphosphate; d) fructose-bisphosphate aldolase class 1 (fbaB) or fructose-bisphosphate aldolase class 2 (fbaA) splitting fructose 1,6-bisphosphate into dihydroxyacetone phosphate and glyceraldehyde 3- phosphate; e) triosephosphate isomerase (tpiA) converting dihydroxyacetone phosphate to D-glyceraldehyde- 3-phosphate; f) glyceraldehyde-3-phosphate dehydrogenase A (gapA) oxidatively phosphorylating D- glyceraldehyde 3-phosphate (G3P) to 1,3-bisphosphoglycerate (BPG) using the cofactor NAD; g) glyceraldehyde-3-phosphate dehydrogenase (gapC) converting D-glyceraldehyde 3-phosphate into 1,3-bisphosphoglyceric acid; h) phosphoglycerate kinase (pgk) dephosphorylating 1,3-bisphosphoglyceric acid to generate 3- phospho-D-glycerate; i) D-3-phosphoglycerate dehydrogenase (serA) oxidizing 3-phospho-D-glycerate to 3- phosphohydroxypyruvate; j) phosphoserine aminotransferase (serC) converting 3-phosphohydroxypyruvate to phosphoserine; or k) phosphoserine phosphatase (serB) dephosphorylating phosphoserine to serine.
[0080] In some aspects, a microbial host cell genetically modified to produce cysteine and/or cystine is provided, wherein the host cell expresses heterologous genes encoding a pyridoxal 5-phosphate (PLP)-dependent enzyme TrpS comprising i) an enzyme subunit having an amino acid sequence comprised in SEQ ID NO: 13 (trpB) and ii) an enzyme subunit having an amino acid sequence comprised in SEQ. ID NO: 14 (trpA), further comprising an operative biosynthetic pathway capable of producing
serine, said pathway comprising one or more pathway polypeptides selected from: a) glucokinase (glk) comprised in SEQ ID NO: 1 phosphorylating glucose to glucose-6-phosphate; b) phosphoglucose isomerase (pgi) comprised in SEQ. ID NO: 2 isomerizing glucose-6-phosphate to fructose-6-phosphate; c) phosphofructokinase 2 (pfkB) comprised in SEQ ID NO: 3 phosphorylating fructose-6-phosphate to fructose-1.6-bisphosphate; d) fructose-bisphosphate aldolase class 1 (fbaB) comprised in SEQ ID NO: 4 or fructose-bisphosphate aldolase class 2 (fbaA) comprised in SEQ ID NO: 5 splitting fructose 1,6-bisphosphate into dihydroxyacetone phosphate and glyceraldehyde 3-phosphate; e) triosephosphate isomerase (tpiA) comprised in SEQ ID NO: 6 converting dihydroxyacetone phosphate to D-glyceraldehyde-3-phosphate; f) glyceraldehyde-3-phosphate dehydrogenase A (gapA) comprised in SEQ ID NO: 7 oxidatively phosphorylating D-glyceraldehyde 3-phosphate (G3P) to 1,3-bisphosphoglycerate (BPG) using the cofactor NAD; g) glyceraldehyde-3-phosphate dehydrogenase (gapC) comprised in SEQ ID NO: 8 converting D- glyceraldehyde 3-phosphate into 1,3-bisphosphoglyceric acid; h) phosphoglycerate kinase (pgk) comprised in SEQ ID NO: 9 dephosphorylating 1,3- bisphosphoglyceric acid to generate 3-phospho-D-glycerate; i) D-3-phosphoglycerate dehydrogenase (serA) comprised in SEQ ID NO: 10 oxidizing 3-phospho-D- glycerate to 3-phosphohydroxypyruvate; j) phosphoserine aminotransferase (serC) comprised in SEQ ID NO: 11 converting 3- phosphohydroxypyruvate to phosphoserine; and/or k) phosphoserine phosphatase (serB) comprised in SEQ ID NO: 12 dephosphorylating phosphoserine to serine.
[0081] Among the said pathway polypeptides the pyridoxal 5-phosphate (PLP)-dependent enzyme is in some embodiments Tryptophan synthase comprising an amino acid sequence which has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the Tryptophan synthase units comprised in SEQ ID NO: 13, 14, 15 or 16. In other embodiments the glucokinase (glk) has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the Glucokinase comprised in SEQ ID NO: 1. In other embodiments the phosphoglucose isomerase (pgi) has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99%
identity, such as 100% identity to the phosphoglucose isomerase (pgi) comprised in SEQ ID NO: 2. In other embodiments the phosphofructokinase 2 (pfkB) has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the phosphofructokinase 2 (pfkB) comprised in SEQ. ID NO: 3. In other embodiments the fructose-bisphosphate aldolase class 1 (fbaB) has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the fructose- bisphosphate aldolase comprised in SEQ ID NO: 4. In other embodiments the fructose-bisphosphate aldolase class 2 (fbaA) has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the fructose-bisphosphate aldolase comprised in SEQ ID NO: 5. In other embodiments the triosephosphate isomerase (tpiA) has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the triosephosphate isomerase comprised in SEQ ID NO: 6. In other embodiments the glyceraldehyde-3-phosphate dehydrogenase A (gapA) has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the glyceraldehyde-3-phosphate dehydrogenase A comprised in SEQ ID NO: 7. In other embodiments the glyceraldehyde-3-phosphate dehydrogenase (gapC) has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the glyceraldehyde-3-phosphate dehydrogenase comprised in SEQ ID NO: 8. In other embodiments the phosphoglycerate kinase (pgk) has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the phosphoglycerate kinase comprised in SEQ ID NO: 9. In other embodiments the D-3- phosphoglycerate dehydrogenase (serA) has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the D-3-phosphoglycerate dehydrogenase comprised in a sequence selected from the group consisting of: SEQ ID NO: 10, SEQ ID NO: 27 , SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, and SEQ ID NO: 47. In one embodiment, the the D-3-phosphoglycerate dehydrogenase (serA) has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90%
identity, such at least 95%, such at least 99% identity, such as 100% identity to the D-3- phosphoglycerate dehydrogenase comprised in: SEQ ID NO: 10. In other embodiments the phosphoserine aminotransferase (serC) has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the phosphoserine aminotransferase comprised in SEQ. ID NO: 11. In other embodiments the phosphoserine phosphatase (serB) has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the phosphoserine phosphatase comprised in SEQ ID NO: 12.
[0082] Additionally or alternatively, the genetically modified host cell comprises and expresses one or more genes encoding the one or more pathway polypeptides, which genes are selected from the group of: a) a gene which has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the gene encoding the Tryptophan synthase comprised in SEQ ID NO: 13, 14, 15 or 16; b) a gene which has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the gene encoding the glucokinase comprised in SEQ ID NO: 1; c) a gene which has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the gene encoding the phosphoglucose isomerase (pgi) comprised in SEQ ID NO: 2; d) a gene which has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the gene encoding the phosphofructokinase 2 (pfkB) comprised in SEQ ID NO: 3; e) a gene which has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the gene encoding the fructose-bisphosphate aldolase comprised in SEQ ID NO: 4; f) a gene which has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the gene encoding the fructose-bisphosphate aldolase
comprised in SEQ ID NO: 5; g) a gene which has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the gene encoding the triosephosphate isomerase comprised in SEQ. ID NO: 6; h) a gene which has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the gene encoding the glyceraldehyde-3-phosphate dehydrogenase A comprised in SEQ ID NO: 7; i) a gene which has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the gene encoding the glyceraldehyde-3-phosphate dehydrogenase comprised in SEQ ID NO: 8; j) a gene which has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the gene encoding the phosphoglycerate kinase comprised in SEQ ID NO: 9; k) a gene which has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the gene encoding D-3-phosphoglycerate dehydrogenase comprised in SEQ ID NO: 10; l) a gene which has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the gene encoding the phosphoserine aminotransferase comprised in SEQ ID NO: 11; and m) a gene which has at least 70% identity, such at least 75% identity, such at least 80% identity, such at least 85% identity, such at least 90% identity, such at least 95%, such at least 99% identity, such as 100% identity to the gene encoding the phosphoserine phosphatase comprised in SEQ ID NO: 12.
[0083] In some embodiments one or more of the said genes and/or pathway polypeptides are heterologous to the host cell and moreover the host cell can comprise two or more copies of one or more of these genes or otherwise overexpressed. In further embodiments the host cell can comprise a transporter molecule facilitating transport of a precursor for or a product of the serine pathway. The host cell can also be further genetically modified to provide an increased amount of a substrate in the
serine pathway, and/or one or more native or endogenous genes of the host cell can be deleted, disrupted and/or attenuated to increase production of serine. Still further the host cell can be further genetically modified to exhibit increased tolerance towards one or more substrates, intermediates, or products in the serine pathway. In some embodiments, the one or more genes to be deleted, disrupted and/or attenuated to increase production of serine are selected from the group consisting of: sdaA (SEQ ID NO: 23), sdaB (SEQ ID NO: 24), tdcG (SEQ ID NO: 25), and glyA (SEQ ID NO: 26) or any homologs or paralogs thereof having at least 90% sequence identity thereto. In some embodiments, the host cell according to the present disclosure is provided wherein one or more native or endogenous genes of the host cell are deleted, disrupted and/or attenuated, wherein the one or more genes are selected from the group consisting of: sdaA, sdaB, tdcG, and glyA.
[0084] The host cell described herein is suitably prokaryotic or eukaryotic such as of the genus Escherichia, optionally of the species Escherichia coli or C. glutamicum.
[0085] In some embodiments, the host cell described herein is a Gram-positive or Gram-negative bacterium.
[0086] Examples of bacteria which can be used according to the present disclosure belong to the Enterobacteriaceae family, such as bacteria belonging to a genus selected from the group consisting of Escherichia, Arsenophonus, Biostraticola, Brenneria, Buchnera, Budvicia, Buttiauxella, Cedecea, Citrobacter, Cosenzaea, Cronobacter, Dickeya, Edwardsiella, Enterobacter, Erwinia, Ewingella, Gibbsiella, Hafnia, Klebsiella, Leclercia, Leminorella, Lonsdalea, Mangrovibacter, Moellerella, Morganella, Obesumbacterium, Pantoea, Pectobacterium, Phaseolibacter, Photorhabdus, Plesiomonas, Proteus, Rahnella, Raoultella, Saccharobacter, Salmonella, Samsonia, Serratia, Shimwellia, Sodalis, Tatumella, Thorsellia, Trabulsiella, Wigglesworthia, Yersinia and Yokenella.
[0087] According to certain other embodiments, the bacterium belongs to a genus selected from the group selected from Escherichia, Bacillus, Lactococcus, Lactobacillus, Clostridium, Corynebacterium, Geobacillus, Streptococcus, Pseudomonas, Streptomyces, Shigella, Acinetobacter, Citrobacter, Salmonella, Klebsiella, Enterobacter, Erwinia, Kluyvera, Serratia, Cedecea, Morganella, Hafnia, Edwardsiella, Providencia, Proteus and Yersinia.
[0088] According to particular embodiments, the bacterium belongs to the genus Escherichia. According to particular embodiments, the bacterium is Escherichia coli. Non-limiting examples of a bacterium belonging to the genus Escherichia, which can be used to derive a host cell of the present disclosure are Escherichia coli K-12 (especially substrain MG1655 or W3110), BL21, W, or Crooks. According to more particular embodiments, the bacterium is Escherichia coli K-12.
[0089] According to other particular embodiments, the bacterium belongs to the genus Corynebacterium. A non-limiting example of a bacterium of the genus Corynebacterium is
Corynebacterium glutamicum. According to other particular embodiments, the bacterium is Corynebacterium glutamicum.
[0090] According to other particular embodiments, the bacterium belongs to the genus Bacillus. Nonlimiting examples of a bacterium of the genus Bacillus are Bacillus subtitlis, Bacillus amyloliquefaciens, Bacillus licheniformis, and Bacillus mojavensis. According to more particular embodiments, the bacterium is Bacillus subtitlis. According to other particular embodiments, the bacterium is Bacillus licheniformis.
[0091] According to other particular embodiments, the bacterium belongs to the genus Lactococcus. A non-limiting example of a bacterium of the genus Lactococcus is Lactococcus lactis. According to other particular embodiments, the bacterium is Lactococcus lactis.
[0092] According to other particular embodiments, the bacterium belongs to the genus Streptomyces. A non-limiting examples of a bacterium of the genus Streptomyces are Streptomyces lividans, Streptomyces coelicolor, or Streptomyces griseus. According to other particular embodiments, the bacterium is Streptomyces lividans. According to other particular embodiments, the bacterium is Streptomyces coelicolor. According to other particular embodiments, the bacterium is Streptomyces griseus.
[0093] According to other particular embodiments, the bacterium belongs to the genus Pseudomonas. A non-limiting example of a bacterium of the genus Pseudomonas is Pseudomonas putida. According to more particular embodiments, the bacterium is Pseudomonas putida.
[0094] As described, supra, an additional aspect of the present disclosure concerns a cell culture, comprising host cell described herein and a fermentation medium and in some embodiments the methods described herein also include steps of: a) culturing the said cell culture at conditions allowing the host cell to produce serine and the pyridoxal 5-phosphate (PLP)-dependent enzyme; and b) feeding the source of sulfur to the fermentation medium.
[0095] The said method can further comprise one or more steps selected from: a) culturing the cell culture under aerobic and/or anaerobic conditions b) culturing the cell culture under agitation; c) culturing the cell culture at a temperature of between 25 to 70 °C; d) culturing the cell culture at a pH of between 6-10; e) culturing the cell culture for between 10 hours to 30 days; and f) culturing the cell culture under fed-batch, repeated fed-batch, continuous, or semi-continuous conditions.
[0096] The methods described herein can also include feeding one or more exogenous serine
precursors to the cell culture.
Sequence listings
[0097] The present application contains a Sequence Listing prepared in Patentin included below but also submitted electronically in ST26 format which is hereby incorporated by reference in its entirety.
Examples
[0098] The following examples further demonstrates the method for producing cysteine/cystine and related aspects.
Materials and methods
[0099] Chemicals used in the examples herein, e.g. for buffers and substrates, are commercial products of at least reagent grade.
Example 1: Generation of L-serine fermentation broth
[0100] The strain and fermentation method described in US20210095245, US10513682, and in Rennig et al., 2019 were used to produce fermentation mediums with high L-serine titers. Briefly, the seed cultures of the strain were grown aerobically in 2xYT medium containing 0.2% glucose, ImM glycine and supplemented with required antibiotics, or in fermentation media as detailed below, until at least an optical density at 600nm (OD600) above 5. Fed batch fermentation was performed at 37°C using a starting batch volume of 40% of the total working reactor volume. The seed inoculation was 2,5% of the batch volume. Dissolved oxygen tension (DO) was maintained at 20% and pH controlled at pH 7,0 +/-0,l using ammonia liquid (15-25% w/v). The batch media contained 2 g/L MgSO4-7H2O, 2 g/L KH2PO4, 10 g/L ammonium sulfate, 60mM glucose or carbohydrate equivalent based on C-mol basis, 2 g/L yeast extract, 0.6 g/L glycine, lx trace elements and 50 mg/L kanamycin. Onset of the fed- batch feeding was initiated by increase of the DO upon depletion of batch glucose. The feed solution contained 650 g/L glucose, 6 g/L glycine and 50 pg/mL kanamycin. Fed-batch fermentation was
performed until a L-serine concentration 50 g/L or more was reached (see figure 2). Upon completion of the fermentation, the fermentation liquid was centrifuged at 4200xg for 20 min at 4°C and the supernatant collected and stored at -80°C until later use. Using this approach, it was possible to generate L-serine fermentation broth with L-serine concentrations >50 g/L without any purification step except removal of biomass. The resulting L-serine fermentation broth was subsequently used as a substrate for tryptophan synthase to produce L-cysteine (see example 3 and 4).
Example 2: Generation of an E. coli BL21 (DE3) strain expressing tryptophan synthase
[0101] A pSEVA27 vector backbone containing the two genes (trpA and trpB) encoding E. coli TrpS was constructed using uracil excision cloning as described in Cavaleiro et al., 2015. Briefly, a pSEVA27 vector backbone fragment was PCR amplified using the oCys_50 and oCys_51 primers (table 1), and TrpS was amplified from the genome of E. coli BI21(DE3). trpB was amplified using primers oCys_48 and oCys_53 (table 1) and trpA using primers oCys_49 and oCys_52 (table 1). Amplification of trpA using these primers generated an n-terminal hexahistidine tag. Each PCR reaction contained 200 nM of forward and reverse primer, 1 X Phusion U mastermix (Thermoscientific, Waltham, MA, USA) and approx. 1 ng of DNA template. The following PCR protocol was used for amplification: An initial denaturation step at 98°C for 40 seconds, followed by 20 cycles of denaturation at 98°C for 12 seconds, annealing at 60°C for 30 seconds, extension at 72°C for 60 seconds. The resulting PCR products were column purified (Nucleospin PCR clean up kit) and subjected to Dpnl (New England Biolabs, Ipswitch, MA, USA) digestion overnight. The digested products were column purified (Nucleospin PCR clean up kit) and concentration was measured using a Nanodrop instrument (Thermoscientific, Waltham, MA, USA). The resulting fragments were assembled using USER enzyme (New England Biolabs, Ipswitch, MA, USA) by incubation at 37°C for 30 min followed by 16°C for 25 min, using a molar ratio of vector to insert of 1:1.5. 2.5 pL of the USER mix was transformed into chemically competent E. coli DH5a cells (New England Biolabs, Ipswitch, MA, USA) using a standard heat shock protocol and 100 pL of the transformed cells plated on LB-kan plates. A single colony was used to inoculate 10 ml of 2xYT media with 50 pg/ml Kanamycin, which was incubated O/N at 37°C and shaking at 250 rpm. Plasmid from the resulting culture was purified (Nucleospin plasmid purification kit) and the plasmid sequence verified by sanger sequencing (Eurofins Scientific, Luxembourg). 100 ng of verified plasmid was transformed into chemically competent E. coli BL21(DE3) using a standard heat shock protocol and 100 pL of the culture plated on LB-Kan agar plates. A single colony from the plate was used to inoculate 10 ml of 2xYT media with 50 pg/ml Kanamycin to generate the final strain expressing tryptophan synthase, subsequently referred to as Cys_39.
Table 1: Primers used for generation of a pSEVA27 vector backbone encoding trpB and trpA with an n-terminal hexahistidine tag.
[0102] This experiment demonstrated the generation of an E. coli BL21(DE3) strain overexpressing E. coli tryptophan synthase (see figure 3) and this strain was subsequently tested for its L-cysteine production capabilities as outlined in example 3.
Example 3: Production of L-cysteine from L-serine and sodium hydrogen sulfide using tryptophan synthase
[0103] To test the L-cysteine production capabilities of Cys_39, a two-step approach was developed. First, bacteria expressing tryptophan synthase were grown by fermentation of Cys_39, followed by whole cell biocatalysis using L-serine and sodium hydrogen sulfide as substate for TrpS.
[0104] The Cys_39 biomass was generated as follows: Seed cultures were grown aerobically in 2xYT medium containing 0.2% glucose, ImM glycine and supplemented with required antibiotics, or in fermentation media as detailed below, until at least an optical density at 600nm (OD600) above 5 was reached. Fed batch fermentation was performed at 32°C using a starting batch volume of 40% of the total working reactor volume. The seed inoculation was 2,5% of the batch volume. Dissolved oxygen tension (DO) was maintained at 30% and pH controlled at pH 7,0 +/-0,l using ammonia liquid (15-25% w/v). The batch media contained 2 g/L MgSO4-7H2O, 2 g/L KH2PO4, 5 g/L ammonium sulfate, 0.5 % Glucose and 0.5 % Glycerol glucose or carbohydrate equivalent based on C-mol basis, 5 g/L yeast extract, 2x trace elements and 50 mg/L kanamycin. Onset of the fed-batch feeding was initiated by increase of the DO upon depletion of batch glycerol, thus the second observed DO increased based on carbohydrate depletion. Fed-batch feeding was controlled as a typical DO-stat fermentation. Upon each DO increase, addition of feed solution was used equal to 2,9% relative to starting batch volume. The feed solution contained 350 g/L glycerol and 10 g/L of Lactose and yeast extract, 50 mg/L kanamycin. Fed-batch fermentation was typically performed for 24 hours with either exponential feeding profile or DO stat or until a biomass concentration of at least OD at 600 nm of 50 was reached
(see figure 4). Upon completion of the fermentation, the fermentation liquid was centrifuged at 4200xg for 20 min at 4°C, the supernatant discarded, and the biomass stored at -80°C until further use.
[0105] The biocatalytic conversion of L-serine to L-cysteine was done by resuspending the previously prepared Cys_39 biomass to an OD at 600 nm between 10 and 40, in 25-100 ml of 99% L-serine (Lake Avenue Nutrition, CA, USA) solution with an L-serine concentration >50 g/L. PLP was added to a final concentration of 0.25 mM. The conversion process was started by addition of 600 g/L sodium hydrogen sulfide (4% of total reaction volume) and incubation of the reaction solution at 37°C and 250 rpm shaking. To supply sufficient hydrogen sulfide ions, a volume corresponding to 4% of the total reaction volume of 600 g/L sodium hydrogen sulfide was added every 30 minutes for the first 2.5 hours of the conversion. The conversion was allowed to proceed for up to 24 hours and the L-serine and L- cysteine followed by HPLC analysis. At high concentrations, L-cysteine was oxidised to its dimeric form, cystine, therefore this was also quantified using HPLC. Samples for HPLC analysis were prepared by taking a sample from the bioconversion vessel and diluting it 1:1 with 1 M H2SO4. This solution was then further diluted 1:50 with deionised water, resulting in a 100-fold final sample dilution. The L- serine, L-cysteine and cystine concentrations was measured using a Dionex Ultimate 3000 HPLC (high- performance liquid chromatography) equipped with a CHIROBIOTIC T Chiral (250 x 2.1 mm x 5 pm) column (Sigma-Aldrich, St. Louis, MO, USA) and a Diode Array Detector (DAD-UV). The mobile phase comprised of 60% acetonitrile (v/v) and 0.02% (v/v) formic acid in Milli-Q. water. The mobile phase was delivered at a rate of 1.0 mL/min. The injection volume was 2.5 pL and the standard curve varied from 0.05 to 2 g/L for all compounds.
[0106] Using this approach, biomass from Cys_39 converted 10 grams of serine to 9.03 grams of L- cysteine and 0.8 grams of cystine (see figure 5). These results confirmed that TrpS could be used to produce L-cysteine from serine and sodium hydrogen sulfide and show that the bioconversion could be followed by HPLC analysis. This method was subsequently used to compare pure L-serine and L- serine fermentation broth as substrates for L-cysteine production (example 4).
Example 4: Conversion of L-serine to L-cysteine using pure L-serine and L-serine fermentation broth as substrates
[0107] To investigate if broth from the L-serine fermentation described in example 1 could be used directly as a substrate for TrpS, the production of L-cysteine from either 99 % pure L-serine (Sigma) or L-serine fermentation broth was compared (see figures 5 to 7). The experiment was conducted as described in example 3, except the Cys_39 biomass was either resuspended in 100 g/L of pure L-serine or L-serine fermentation broth with a L-serine concentration of 100 g/L. The L-serine, L-cysteine, and
cystine concentrations were followed by HPLC for five hours after which all the added L-serine, both pure and in the fermentation broth, had been consumed (figure 5). L-serine consumption rates did not vary with the L-serine source, with all L-serine being consumed after four hours in both the pure L-serine and L-serine fermentation broth sample. Correspondingly, L-cysteine and cystine production rates were similar and independent of the L-serine being pure or from fermentation broth (figures 6 and 7). These results clearly showed that a complex L-serine fermentation broth, in combination with a hydrogen sulfide donor such as sodium hydrogen sulfide, can be used as a substrate for TrpS to efficiently produce L-cysteine. Furthermore, unexpectedly the L-serine fermentation broth is comparable to pure L-serine as a substrate for TrpS. Using L-serine fermentation broth as opposed to pure L-serine avoids expensive downstream processing steps associated with L-serine purification.
Example 5: Downstream purification steps that can be avoided when using serine fermentation broth as a substrate for TrpS.
[0108] The separation of amino acids from the fermentation broth is usually done by centrifugation or filtration followed by a purification steps using chromatographic techniques chosen according to the product properties such as solubility, isoelectric point, and affinity to adsorbent (Hermann, 2003). In this instance the SuperPro Designer (Intelligen inc) software was used to design an in silica downstream purification process for L-serine. The designed process was based on the downstream process currently used to purify the amino acid L-threonine from fermentation broth. L-threonine and L-serine are chemically almost identical, with the only difference being that L-threonine has an extra methyl substituent on the R-carbon. Considering their similarities, including an identical functional hydroxyl group, the downstream process for L-serine purification was expected to be similar to the process used for L-threonine.
[0109] The designed in silica L-serine downstream purification process consists of five main sections: separation, primary purification, concentration, secondary purification, and product recovery. Briefly described the process was as follows: After the serine fermentation has been stopped, the biomass was separated from the fermentation broth by centrifugation. In the primary purification step, the resulting supernatant was loaded onto an ion exchange column, removing the target product from the aqueous feed. After elution, the product solution is pumped into an activated carbon bed to remove any coloured compounds. Next, ammonia was removed, and the resulting product concentrated using a multi-stage evaporator to remove any excess water. The concentrated L-serine liquor was then crystallised, and the crystals recovered and passed through a rotary vacuum filter to generate product of greater than 95% purity (see figure 8).
[0110] The downstream process described above is expected to take approximately 30 hours and
requires the purchase, maintenance, and operation of a selection of expensive equipment. In addition to this, the numerous removal operations necessary to obtain the required serine purity is expected to result in a significant loss of product as this has been observed for several other amino acids produced via fermentation (D'Este et al., 2018; Hermann, 2003; Kumar et al., 2014). Considering these observations, it is highly desirable to eliminate the need for the expensive and tedious downstream purification process. This is achieved by the disclosed invention, where serine fermentation broth as opposed to pure serine is used as a substrate for TrpS when producing L-cysteine.
References
Cavaleiro, A. M., Kim, S. H., Seppala, S., Nielsen, M. T., & Nprholm, M. H. H. (2015). Accurate DNA Assembly and Genome Engineering with Optimized Uracil Excision Cloning. ACS Synthetic Biology, 4(9), 1042-1046. https://doi.org/10.1021/acssynbio.5b00113
D'Este, M., Alvarado-Morales, M., & Angelidaki, I. (2018). Amino acids production focusing on fermentation technologies - A review. Biotechnology Advances, 36(1), 14-25. https://doi.Org/10.1016/j.biotechadv.2017.09.001
Esaki, N., Tanaka, H., Soda, K., & Miles, E. W. (1983). Enzymatic Synthesis of S-Substituted L-Cysteines with Tryptophan Synthase of Escherichia coli. Agricultural and Biological Chemistry, 47(12), 2861- 2864. https://doi.org/10.1271/bbbl961.47.2861
Hamilton, B. K., Hsiao, H. Y., Swann, W. E., Anderson, D. M., & Delente, J. J. (1985). Manufacture of I- amino acids with bioreactors. Trends in Biotechnology, 3(3), 64-68. https://doi.org/10.1016/0167- 7799(85)90079-4
Hashim, Y., Ismail, N., Jamal, P., Othman, R., & Salleh, H. (2014). Production of Cysteine: Approaches, Challenges and Potential Solution. International Journal of Biotechnology for Wellness Industries, 3(3), 95-101. https://doi.Org/10.6000/1927-3037.2014.03.03.3
Hermann, T. (2003). Industrial production of amino acids by coryneform bacteria. Journal of Biotechnology, 104(1-3), 155-172. https://doi.org/10.1016/S0168-1656(03)00149-4
Ishiwata, K., Nakamura, T., Shimada, M., & Makiguchi, N. (1989). Enzymatic production of l-cysteine
with tryptophan synthase of Escherichia coli. Journal of Fermentation and Bioengineering, 67(3), 169-
172. https://doi.org/10.1016/0922-338X(89)90116-5
Kumar, R., Vikramachakravarthi, D., & Pal, P. (2014). Production and purification of glutamic acid: A critical review towards process intensification. Chemical Engineering and Processing: Process Intensification, 81, 59-71. https://doi.Org/10.1016/j.cep.2014.04.012
Raboni, S., Bettati, S., & Mozzarelli, A. (2009). Tryptophan synthase: a mine for enzymologists. Cellular and Molecular Life Sciences, 66(14), 2391-2403. https://doi.org/10.1007/s00018-009-0028-0
Rennig, M., Mundhada, H., Wordofa, G. G., Gerngross, D., Wulff, T., Worberg, A., Nielsen, A. T., & Nprholm, M. H. H. (2019). Industrializing a Bacterial Strain for <scp>l</scp> -Serine Production through Translation Initiation Optimization. ACS Synthetic Biology, 8(10), 2347-2358. https://doi.org/10.1021/acssynbio.9b00169
Watkins-Dulaney, E. J., Straathof, S., & Arnold, F. H. (2020). Tryptophan Synthase: Biocatalyst Extraordinaire. Chembiochem : A European Journal of Chemical Biology. https://doi.org/10.1002/cbic.202000379
Xu, L., Wang, Z., Mao, P., Liu, J., Zhang, FL, Liu, Q.., & Jiao, Q..-C. (2013). Enzymatic synthesis of S-phenyl- L-cysteine from keratin hydrolysis industries wastewater with tryptophan synthase. Bioresource Technology, 133, 635-637. https://doi.Org/10.1016/j.biortech.2013.02.011
Yang, Z. (2009). Hofmeister effects: an explanation for the impact of ionic liquids on biocatalysis. Journal of Biotechnology, 144(1), 12-22. https://doi.Org/10.1016/j.jbiotec.2009.04.011
* * *
Claims
1. A method for producing cysteine and/or cystine comprising a) providing a fermentation medium comprising serine from of a genetically engineered host cell producing said serine; b) providing one or more sources of sulfur; c) providing one or more pyridoxal 5-phosphate (PLP)-dependent enzymes capable of converting serine into cysteine and/or cystine in the presence of the source of sulfur; d) contacting the serine in the fermentation medium with the pyridoxal 5-phosphate (PLP)- dependent enzyme in the presence of PLP and the source of sulfur under conditions allowing the serine to be converted into cysteine and/or cystine; and optionally e) recovering and/or isolating the cysteine and/or cystine.
2. The method of any preceding claim, wherein the cysteine and cystine is L-cysteine and/or L-cystine.
3. The method of any preceding claim, further comprising the step of converting the monomeric cysteine to the dimeric cystine.
4. The method of any preceding claim, wherein the fermentation medium further comprises metabolites and/or cells and/or cell debris from the serine producing host cell.
5. The method of any preceding claim, wherein the fermentation medium further comprises ammonium ions, optionally between 0,1 g/L to 20 g/L, optionally between 0,5 g/L to 15 g/L, optionally between 1 g/L to 10 g/L, optionally between 2 g/L to 5 g/L of ammonium ions.
6. The method of any preceding claim, wherein the fermentation medium further comprises phosphate ions, optionally between 0,01 g/L to 10 g/L, optionally between 0,02 g/L to 5 g/L, optionally between 0,05 g/L to 2 g/L of phosphate ions.
7. The method of any preceding claim, wherein the fermentation medium further comprises proteins, DNA and RNA liberated by the host cells.
8. The method of any preceding claim, wherein the fermentation medium further comprises ive cells and/or cell debris, optionally between 0,1 %wt to 75 %wt, optionally between 0,5 %wt to 50 %wt,
optionally between 1 %wt to 40 %wt, optionally between 2 %wt to 35 %wt, optionally between 3 %wt to 30 %wt, optionally between 5 %wt to 25 %wt, optionally between 10 %wt to 20 %wt.
9. The method of any preceding claim, wherein the fermentation medium further comprises N-acetyl serine, optionally between 0,05 g/L to 20 g/L, optionally between 0,1 g/L to 10 g/L, optionally between 0,5 g/L to 2 g/L of N-acetyl serine.
10. The method of any preceding claim, wherein the fermentation medium further comprises one or more metabolites of a host cell selected from glucose-6-phosphate, fructose-l,6-phosphate, glyceraldehyde-3-phosphate, dihydroxyacetone phosphate, 1,3-diphosphoglycerate, 3- phosphoglycerate, 3-phosphopyrovate, and/or 3-phosphoserine.
11. The method of any preceding claim, wherein the fermentation medium further comprises one or more components selected from: a) a carbon source, optionally selected from glycerol; carbohydrates (such as monosaccharides and/or disaccharides; complex sources (such as molasses, fats and oils, and/or starch biomass; b) a nitrogen source, optionally selected from ammonium compounds, nitrates, Urea and/or Amino acids such as alanine arginine, Leucine, and/or D,L-aspartate; c) a phosphate source, optionally selected from potassium phosphate; d) a sulfate source, optionally selected from ammonium sulfate and/or magnesium sulfate; and/or e) trace elements, optionally selected from Fe, Zn, Cu, Mn, Mo, Co, and/or Ni.
12. The method of any preceding claim, wherein the fermentation medium further comprises at least 0,1 pM of pyridoxal 5-phosphate (PLP cofactor).
13. The method of any preceding claim, wherein the fermentation medium comprises at least 10 g/L of serine, such as between 50 to 500 g/L by weight of serine, optionally prior to conversion of any serine into cysteine and/or cystine.
14. The method of any preceding claim, wherein the fermentation medium prior to removal of biomass has an optical density (OD) at 600 nm of at least 1.
15. The method of any preceding claim, wherein the one or more sources of sulfur is capable of forming HS" ions, optionally selected from H2S, S2-, and NaHS.
16. The method of any preceding claim, wherein the one or more sources of sulfur comprises hydrogen sulfide.
17. The method of any preceding claim, wherein the one or more sources of sulfur comprises basic compounds, optionally strongly basic or comprises acidic compounds, optionally strongly acidic.
18. The method of any preceding claim, wherein the fermentation medium comprises a concentration of at least 0,1 % wt of the one or more sources of sulfur.
19. The method of any preceding claim, wherein the conecentration of at least 0,1 % wt of the one or more sources of sulfur in the fermentations mediums is maintained during the conversion of serine to cysteine.
20. The method of any preceding claim, wherein the pyridoxal 5-phosphate (PLP)-dependent enzyme is derived from a bacterium.
21. The method of any preceding claim, wherein the pyridoxal 5-phosphate (PLP)-dependent enzyme is selected from lyases (EC 4.-.-.-), carbon oxygen lyases (EC 4.2.-.-), and/or hydro-lyases (EC 4.2.1.-).
22. The method of any preceding claim, wherein the pyridoxal 5-phosphate (PLP)-dependent enzyme comprises a fold type II configuration.
23. The method of any preceding claim, wherein the pyridoxal 5-phosphate (PLP)-dependent enzyme is a Tryptophan synthase (TrpS), optionally comprising an amino acid sequence which has at least 70% identity to one or more of SEQ ID NO: 13 (trpB), 14 (trpA), 15 or 16.
24. The method of any preceding claim, wherein the pyridoxal 5-phosphate (PLP)-dependent enzyme comprises one or more mutations outside the PLP binding site and/or outside the substrate binding site.
25. The method of claim 24, wherein the PLP binding site of the pyridoxal 5-phosphate (PLP)- dependent enzyme comprises one or more amino acid moieties corresponding to position H86, K87, Q114, T190, C230, G232, G233, G234, S235, N236, A237, G303, E350, S377, or G378 of SEQ. ID NO: 15
or 16.
26. The method of claim 24, wherein the substrate binding site of the pyridoxal 5-phosphate (PLP)- dependent enzyme comprises one or more amino acid moieties corresponding to position N305, A112, Gill, T110, Q.114, H115, G113, or E109 of SEQ ID NO: 15 or 16
27. The method of any preceding claim, wherein the pyridoxal 5-phosphate (PLP)-dependent enzyme comprises one or more mutations selected from D47S and L81V in the corresponding amino acid sequence of SEQ ID NO: 15 or 16 or conservative substitutions thereof.
28. The method of any preceding claim, wherein at least 50% of the serine in the fermentation medium is converted to cysteine and/or cystine.
29. The method of any preceding claim, further comprising one or more steps selected from a) Phosphorylation of glucose by Glucokinase (glk) to generate glucose-6-phosphate; b) Isomerisation of glucose-6-phosphate by phosphoglucose isomerase (pgi) to generate fructose- 6-phosphate; c) Phosphorylation of fructose-6-phosphate by phosphofructokinase 2(pfkB) to generate fructose- 1.6-bisphosphate; d) Splitting of fructose 1,6-bisphosphate by fructose-bisphosphate aldolase class 1 (fbaB) or fructose-bisphosphate aldolase class 2 (fbaA) into dihydroxyacetone phosphate and glyceraldehyde 3-phosphate; e) Conversion of dihydroxyacetone phosphate by triosephosphate isomerase (tpiA) to D- glyceraldehyde-3-phosphate; f) oxidative phosphorylation of D-glyceraldehyde 3-phosphate (G3P) by glyceraldehyde-3- phosphate dehydrogenase A (gapA) to 1,3-bisphosphoglycerate (BPG) using the cofactor NAD; g) conversion of D-glyceraldehyde 3-phosphate by glyceraldehyde-3-phosphate dehydrogenase (gapC) into 1,3-bisphosphoglyceric acid; h) Dephosphorylation of 1,3-bisphosphoglyceric acid by phosphoglycerate kinase (pgk) to generate 3-phospho-D-glycerate; i) oxidation of 3-phospho-D-glycerate by D-3-phosphoglycerate dehydrogenase (serA) to 3- phosphohydroxypyruvate; j) conversion of 3-phosphohydroxypyruvate by phosphoserine aminotransferase (serC) to phosphoserine; or
k) dephosphorylation of phosphoserine by phosphoserine phosphatase (serB) to serine.
30. The method of claim, further comprises a) oxidation of 3-phospho-D-glycerate by D-3-phosphoglycerate dehydrogenase (serA) to 3- phosphohydroxypyruvate; b) conversion of 3-phosphohydroxypyruvate by phosphoserine aminotransferase (serC) to phosphoserine; and c) dephosphorylation of phosphoserine by phosphoserine phosphatase (serB) to serine.
31. The method of claim 29, wherein the a) glucokinase (glk) has at least 70% identity to the Glucokinase comprised in SEQ ID NO: 1; b) phosphoglucose isomerase (pgi) has at least 70% identity to the phosphoglucose isomerase (pgi) comprised in SEQ. ID NO: 2; c) phosphofructokinase 2 (pfkB) has at least 70% identity to the phosphofructokinase 2 (pfkB) comprised in SEQ ID NO: 3; d) fructose-bisphosphate aldolase class 1 (fbaB) has at least 70% identity to the fructosebisphosphate aldolase comprised in SEQ ID NO: 4; e) fructose-bisphosphate aldolase class 2 (fbaA) has at least 70% identity to the fructose- bisphosphate aldolase comprised in SEQ ID NO: 5; f) triosephosphate isomerase (tpiA) has at least 70% identity to the triosephosphate isomerase comprised in SEQ ID NO: 6; g) glyceraldehyde-3-phosphate dehydrogenase A (gapA) has at least 70% identity to the glyceraldehyde-3-phosphate dehydrogenase A comprised in SEQ ID NO: 7; h) glyceraldehyde-3-phosphate dehydrogenase (gapC) has at least 70% identity to the glyceraldehyde-3-phosphate dehydrogenase comprised in SEQ ID NO: 8; i) phosphoglycerate kinase (pgk) has at least 70% identity to the phosphoglycerate kinase comprised in SEQ ID NO: 9; j) D-3-phosphoglycerate dehydrogenase (serA) has at least 70% identity to the D-3- phosphoglycerate dehydrogenase comprised in a sequence selected from the group consisting of: SEQ ID NO: 10, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, and SEQ ID NO: 47, optionally in SEQ ID NO: 10;
k) phosphoserine aminotransferase (serC) has at least 70% identity to the phosphoserine aminotransferase comprised in SEQ ID NO: 11; and l) phosphoserine phosphatase (serB) has at least 70% identity to the phosphoserine phosphatase comprised in SEQ. ID NO: 12.
32. The method of any preceding claim, wherein the pH in the fermentation medium is from about 6 to about 10.
33. The method of any preceding claim, wherein the temperature in the fermentation medium is from about 25°C to about 60°C.
34. The method of any preceding claim, wherein the recovery and/or isolation of cysteine and/or cystine comprises one or more steps selected from: a) contacting the fermentation medium with one or more adsorbent resins to obtain at least a portion of the produced cysteine and/or cystine; b) contacting the fermentation medium with one or more ion exchange or reverse phase chromatography columns in order to obtain at least a portion of the cysteine and/or cystine; c) extracting the cysteine and/or cystine from the fermentation medium; and d) precipitating the cysteine and/or cystine by crystallization or evaporating the solvent of the liquid phase; and optionally isolating cysteine and/or cystine by filtration or gravity separation; thereby recovering and/or isolating the cysteine and/or cystine.
35. A fermentation medium comprising cystiene and/or cystine, obtainable from the method of any preceding claim.
36. The fermentation medium of claim 35 comprising the cysteine and/or cystine and one or more compounds selected from: a) PLP; b) a source of sulfur; c) serine d) a pyridoxal 5-phosphate (PLP)-dependent enzyme; e) one or more fermentation compounds selected from glucose-6-phosphate, fructose-1,6- phosphate, glyceraldehyde-3-phosphate, dihydroxyacetone phosphate, 1,3- diphosphoglycerate, 3-phosphoglycerate, 3-phosphopyrovate, 3-phosphoserine, glycerol,
monosaccharides, disaccharides, ammonium compounds, nitrates, urea, alanine, arginine, Leucine, D-aspartate, potassium phosphate, ammonium sulfate, magnesium sulfate, Fe, Zn, Cu, Mn, Mo, Co, and/or Ni; wherein the concentration of cysteine and/or cystine is at least 0,1 % by weight.
37. A composition comprising the fermentation medium of claim 35 to 36 and one or more agents, additives and/or excipients.
38. The composition of claim 37, wherein the fermentation medium is processed into in a dry solid form.
39. The composition of claim 37, wherein the composition is processed into a liquid stabilized form.
40. A microbial host cell genetically modified to produce cysteine and/or cystine, wherein the host cell expresses a heterologous gene encoding a pyridoxal 5-phosphate (PLP)-dependent enzyme and comprises an operative biosynthetic pathway capable of producing serine, said pathway comprising one or more pathway polypeptides selected from: a) glucokinase (glk) phosphorylating glucose to glucose-6-phosphate; b) phosphoglucose isomerase (pgi) isomerizing glucose-6-phosphate to fructose-6-phosphate; c) phosphofructokinase 2(pfkB) phosphorylating fructose-6-phosphate to fructose-1.6- bisphosphate; d) fructose-bisphosphate aldolase class 1 (fbaB) or fructose-bisphosphate aldolase class 2 (fbaA) splitting fructose 1,6-bisphosphate into dihydroxyacetone phosphate and glyceraldehyde 3- phosphate; e) triosephosphate isomerase (tpiA) converting dihydroxyacetone phosphate to D-glyceraldehyde- 3-phosphate; f) glyceraldehyde-3-phosphate dehydrogenase A (gapA) oxidatively phosphorylating D- glyceraldehyde 3-phosphate (G3P) to 1,3-bisphosphoglycerate (BPG) using the cofactor NAD; g) glyceraldehyde-3-phosphate dehydrogenase (gapC) converting D-glyceraldehyde 3-phosphate into 1,3-bisphosphoglyceric acid; h) phosphoglycerate kinase (pgk) dephosphorylating 1,3-bisphosphoglyceric acid to generate 3- phospho-D-glycerate; i) D-3-phosphoglycerate dehydrogenase (serA) oxidizing 3-phospho-D-glycerate to 3- phosphohydroxypyruvate;
j) phosphoserine aminotransferase (serC) converting 3-phosphohydroxypyruvate to phosphoserine; or k) phosphoserine phosphatase (serB) dephosphorylating phosphoserine to serine.
41. The host cell of claim 40, wherein the pathway comprises: a) oxidation of 3-phospho-D-glycerate by D-3-phosphoglycerate dehydrogenase (serA) to 3- phosphohydroxypyruvate; b) conversion of 3-phosphohydroxypyruvate by phosphoserine aminotransferase (serC) to phosphoserine; and c) dephosphorylation of phosphoserine by phosphoserine phosphatase (serB) to serine.
42. The host cell of claim 40 to 41, wherein the: a) pyridoxal 5-phosphate (PLP)-dependent enzyme is Tryptophan synthase comprising an amino acid sequence which has at least 70% identity to the Tryptophan synthase units comprised in SEQ ID NO: 13, 14, 15 or 16; b) glucokinase (glk) has at least 70% identity to the Glucokinase comprised in SEQ. ID NO: 1; c) phosphoglucose isomerase (pgi) has at least 70% identity to the phosphoglucose isomerase (pgi) comprised in SEQ ID NO: 2; d) phosphofructokinase 2 (pfkB) has at least 70% identity to the phosphofructokinase 2 (pfkB) comprised in SEQ ID NO: 3; e) fructose-bisphosphate aldolase class 1 (fbaB) has at least 70% identity to the fructosebisphosphate aldolase comprised in SEQ ID NO: 4; f) fructose-bisphosphate aldolase class 2 (fbaA) has at least 70% identity to the fructose- bisphosphate aldolase comprised in SEQ ID NO: 5; g) triosephosphate isomerase (tpiA) has at least 70% identity to the triosephosphate isomerase comprised in SEQ ID NO: 6; h) glyceraldehyde-3-phosphate dehydrogenase A (gapA) has at least 70% identity to the glyceraldehyde-3-phosphate dehydrogenase A comprised in SEQ ID NO: 7; i) glyceraldehyde-3-phosphate dehydrogenase (gapC) has at least 70% identity to the glyceraldehyde-3-phosphate dehydrogenase comprised in SEQ ID NO: 8; j) phosphoglycerate kinase (pgk) has at least 70% identity to the phosphoglycerate kinase comprised in SEQ ID NO: 9; k) D-3-phosphoglycerate dehydrogenase (serA) has at least 70% identity to the D-3-
phosphoglycerate dehydrogenase comprised in a sequence selected from the group consisting of: SEQ ID NO: 10, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, and SEQ ID NO: 47, optionally in SEQ ID NO: 10; l) phosphoserine aminotransferase (serC) has at least 70% identity to the phosphoserine aminotransferase comprised in SEQ ID NO: 11; or m) phosphoserine phosphatase (serB) has at least 70% identity to the phosphoserine phosphatase comprised in SEQ ID NO: 12.
43. The host cell of claim 40 to 42, wherein the one or more pathway polypeptides are encoding by one or more genes selected from the group of: a) a gene which is at least 70% identical to the gene encoding the Tryptophan synthase comprised in SEQ ID NO: 13, 14, 15 or 16; b) a gene which is at least 70% identical to the gene encoding the glucokinase comprised in SEQ ID NO: 1; c) a gene which is at least 70% identical to the gene encoding the phosphoglucose isomerase (pgi) comprised in SEQ ID NO: 2; d) a gene which is at least 70% identical to the gene encoding the phosphofructokinase 2 (pfkB) comprised in SEQ ID NO: 3; e) a gene which is at least 70% identical to the gene encoding the fructose-bisphosphate aldolase comprised in SEQ ID NO: 4; f) a gene which is at least 70% identical to the gene encoding the fructose-bisphosphate aldolase comprised in SEQ ID NO: 5; g) a gene which is at least 70% identical to the gene encoding the triosephosphate isomerase comprised in SEQ ID NO: 6; h) a gene which is at least 70% identical to the gene encoding the glyceraldehyde-3-phosphate dehydrogenase A comprised in SEQ ID NO: 7; i) a gene which is at least 70% identical to the gene encoding the glyceraldehyde-3-phosphate dehydrogenase comprised in SEQ ID NO: 8; j) a gene which is at least 70% identical to the gene encoding the phosphoglycerate kinase comprised in SEQ ID NO: 9; k) a gene which is at least 70% identical to the gene encoding D-3-phosphoglycerate
dehydrogenase comprised in a sequence selected from the group consisting of: SEQ ID NO: 10, SEQ. ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, and SEQ ID NO: 47, optionally in SEQ ID NO: 10; l) a gene which is at least 70% identical to the gene encoding the phosphoserine aminotransferase comprised in SEQ ID NO: 11; and m) a gene which is at least 70% identical to the gene encoding the phosphoserine phosphatase comprised in SEQ ID NO: 12.
44. The host cell of claim 40 to 43, wherein one or more genes and/or polypeptides of the pathway for serine are heterologous to the host cell.
45. The host cell of claim 40 to 44, further comprising at least 2 copies of one or more genes ecoding a pathway element of the pathway for serine.
46. The host cell of claim 40 to 45, further comprising a transporter molecule facilitating transport of a precursor for or a product of the pathway for serine.
47. The host cell of claim 40 to 46, wherein the host cell is further genetically modified to provide an increased amount of a substrate in the pathway for serine.
48. The host cell of claim 40 to 47, wherein one or more native or endogenous genes of the host cell are deleted, disrupted and/or attenuated.
49. The host cell of claim 40 to 48, wherein the host cell is further genetically modified to exhibit increased tolerance towards one or more substrates, intermediates, or products in the pathway for serine.
50. The host cell of claim 40 to 49, wherein one or more genes in the pathway for the serine compound are overexpressed.
51. The host cell of claim 40 to 50, wherein the host cell is prokaryotic or eukaryotic.
52. The host cell of claim 51, wherein the host cell is prokaryotic and of the genus Escherichia, optionally of the species Escherichia coli.
53. A cell culture, comprising host cell of claims 40 to 52 and a fermentation medium.
54. The method of claim 1 to 34 further comprising: a) culturing the cell culture of claim 53 at conditions allowing the host cell to produce the serine and the pyridoxal 5-phosphate (PLP)-dependent enzyme; and b) feeding the source of sulfur to the fermentation medium.
55. The method of claim 1 to 34 and 54 further comprising one or more steps selected from: a) culturing the cell culture under aerobic and/or anaerobic conditions b) culturing the cell culture under agitation; c) culturing the cell culture at a temperature of between 25 to 70 °C; e) culturing the cell culture at a pH of between 3-9; f) culturing the cell culture for between 10 hours to 30 days; and g) culturing the cell culture under fed-batch, repeated fed-batch, continuous, or semi-continuous conditions.
56. The method of claim 55 further comprising feeding one or more exogenous serine precursors to the cell culture.
* * *
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22185270 | 2022-07-15 | ||
EP22185270.0 | 2022-07-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024013258A1 true WO2024013258A1 (en) | 2024-01-18 |
Family
ID=82608537
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2023/069370 WO2024013258A1 (en) | 2022-07-15 | 2023-07-12 | Production of cysteine or cystine from serine in fermentation medium |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024013258A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016120326A1 (en) * | 2015-01-27 | 2016-08-04 | Danmarks Tekniske Universitet | Method for the production of l-serine using genetically engineered microorganisms deficient in serine degradation pathways |
CN108342425A (en) * | 2018-05-10 | 2018-07-31 | 南京大学 | A kind of method that enzymatic conversion method prepares DL-cysteine |
CN112813012A (en) * | 2020-12-18 | 2021-05-18 | 浙江新和成股份有限公司 | Genetically engineered bacterium, preparation method thereof and application thereof in cysteine production |
-
2023
- 2023-07-12 WO PCT/EP2023/069370 patent/WO2024013258A1/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016120326A1 (en) * | 2015-01-27 | 2016-08-04 | Danmarks Tekniske Universitet | Method for the production of l-serine using genetically engineered microorganisms deficient in serine degradation pathways |
US10513682B2 (en) | 2015-01-27 | 2019-12-24 | Cysbio Aps | Method for the production of L-serine using genetically engineered microorganisms deficient in serine degradation pathways |
US20210095245A1 (en) | 2015-01-27 | 2021-04-01 | Cysbio Aps | Genetically modified microorganisms having improved tolerance towards l-serine |
CN108342425A (en) * | 2018-05-10 | 2018-07-31 | 南京大学 | A kind of method that enzymatic conversion method prepares DL-cysteine |
CN112813012A (en) * | 2020-12-18 | 2021-05-18 | 浙江新和成股份有限公司 | Genetically engineered bacterium, preparation method thereof and application thereof in cysteine production |
Non-Patent Citations (22)
Title |
---|
"Eur. J. Bio-chem.", vol. 223, 1994, ACADEMIC PRESS, article "Enzyme Nomenclature 1992 from NC-IUBMB", pages: 1 - 5 |
CAVALEIRO, A. M.KIM, S. H.SEPPALA, S.NIELSEN, M. T.NPRHOLM, M. H. H.: "Accurate DNA Assembly and Genome Engineering with Optimized Uracil Excision Cloning", ACS SYNTHETIC BIOLOGY, vol. 4, no. 9, 2015, pages 1042 - 1046, Retrieved from the Internet <URL:https://doi.org/10.1021/acssynbio.5b00113> |
D'ESTE, M.ALVARADO-MORALES, M.ANGELIDAKI, I.: "Amino acids production focusing on fermentation technologies - A review", BIOTECHNOLOGY ADVANCES, vol. 36, no. 1, 2018, pages 14 - 25, Retrieved from the Internet <URL:https://doi.org/10.1016/j.biotechadv.2017.09.001> |
ESAKI, N.TANAKA, H.SODA, K.MILES, E. W.: "Enzymatic Synthesis of S-Substituted L-Cysteines with Tryptophan Synthase of Escherichia coli", AGRICULTURAL AND BIOLOGICAL CHEMISTRY, vol. 47, no. 12, 1983, pages 2861 - 2864, Retrieved from the Internet <URL:https://doi.org/10.1271/bbb1961.47.2861> |
EUR. J. BIOCHEM., vol. 232, 1995, pages 1 - 6 |
EUR. J. BIOCHEM., vol. 237, 1996, pages 1 - 5 |
EUR. J. BIOCHEM., vol. 250, 1997, pages 1 - 6 |
EUR. J. BIOCHEM., vol. 264, 1999, pages 610 - 650 |
HAMILTON, B. K.HSIAO, H. Y.SWANN, W. E.ANDERSON, D. M.DELENTE, J. J.: "Manufacture of I-amino acids with bioreactors", TRENDS IN BIOTECHNOLOGY, vol. 3, no. 3, 1985, pages 64 - 68, XP023595290, Retrieved from the Internet <URL:https://doi.org/10.1016/0167-7799(85)90079-4> DOI: 10.1016/0167-7799(85)90079-4 |
HASHIM, Y.ISMAIL, N.JAMAL, P.OTHMAN, R.SALLEH, H.: "Production of Cysteine: Approaches, Challenges and Potential Solution", INTERNATIONAL JOURNAL OF BIOTECHNOLOGY FOR WELLNESS INDUSTRIES, vol. 3, no. 3, 2014, pages 95 - 101, Retrieved from the Internet <URL:https://doi.org/10.6000/1927-3037.2014.03.03.3> |
HERMANN, T.: "Industrial production of amino acids by coryneform bacteria", JOURNAL OF BIOTECHNOLOGY, vol. 104, no. 1-3, 2003, pages 155 - 172, XP001184757, Retrieved from the Internet <URL:https://doi.org/10.1016/S0168-1656(03)00149-4> DOI: 10.1016/S0168-1656(03)00149-4 |
ISHIWATA K I ET AL: "Enzymatic production of l-cysteine with tryptophan synthase of Escherichia coli", JOURNAL OF FERMENTATION AND BIOENGINEERING, SOCIETY OF FERMENTATION TECHNOLOGY, JP, vol. 67, no. 3, 1 January 1989 (1989-01-01), pages 169 - 172, XP025844649, ISSN: 0922-338X, [retrieved on 19890101], DOI: 10.1016/0922-338X(89)90116-5 * |
ISHIWATA, K.NAKAMURA, T.SHIMADA, M.MAKIGUCHI, N.: "Enzymatic production of I-cysteine with tryptophan synthase of Escherichia coli", JOURNAL OF FERMENTATION AND BIOENGINEERING, vol. 67, no. 3, 1989, pages 169 - 172, XP025844649, Retrieved from the Internet <URL:https://doi.org/10.1016/0922-338X(89)90116-5> DOI: 10.1016/0922-338X(89)90116-5 |
KUMAR, R.VIKRAMACHAKRAVARTHI, D.PAL, P.: "Production and purification of glutamic acid: A critical review towards process intensification", CHEMICAL ENGINEERING AND PROCESSING: PROCESS INTENSIFICATION, vol. 81, 2014, pages 59 - 71, Retrieved from the Internet <URL:https://doi.org/10.1016/j.cep.2014.04.012> |
NEEDLEMANWUNSCH, J. MOL. BIOL., vol. 48, 1970, pages 443 - 453 |
RABONI, S.BETTATI, S.MOZZARELLI, A.: "Tryptophan synthase: a mine for enzymologists", CELLULAR AND MOLECULAR LIFE SCIENCES, vol. 66, no. 14, 2009, pages 2391 - 2403, XP019736004, Retrieved from the Internet <URL:https://doi.org/10.1007/s00018-009-0028-0> DOI: 10.1007/s00018-009-0028-0 |
RENNIG, M.MUNDHADA, H.WORDOFA, G. G.GERNGROSS, D.WULFF, T.WORBERG, A.NIELSEN, A. T.NPRHOLM, M. H. H.: "Industrializing a Bacterial Strain for <scp>I</scp> -Serine Production through Translation Initiation Optimization", ACS SYNTHETIC BIOLOGY, vol. 8, no. 10, 2019, pages 2347 - 2358, Retrieved from the Internet <URL:https://doi.org/10.1021/acssynbio.9b00169> |
RICE ET AL., EMBOSS: THE EUROPEAN MOLECULAR BIOLOGY OPEN SOFTWARE SUITE, 2000 |
RICE ET AL.: "EMBOSS: The European Molecular Biology Open Software Suite", TRENDS GENET., vol. 16, 2000, pages 276 - 277, XP004200114, DOI: 10.1016/S0168-9525(00)02024-2 |
WATKINS-DULANEY, E. J.STRAATHOF, S.ARNOLD, F. H.: "Tryptophan Synthase: Biocatalyst Extraordinaire", CHEMBIOCHEM : A EUROPEAN JOURNAL OF CHEMICAL BIOLOGY, 2020, Retrieved from the Internet <URL:https://doi.org/10.1002/cbic.202000379> |
XU, L.WANG, Z.MAO, P.LIU, J.ZHANG, H.LIU, Q.JIAO, Q.-C.: "Enzymatic synthesis of S-phenyl-L-cysteine from keratin hydrolysis industries wastewater with tryptophan synthase", BIORESOURCE TECHNOLOGY, vol. 133, 2013, pages 635 - 637, Retrieved from the Internet <URL:https://doi.org/10.1016/j.biortech.2013.02.011> |
YANG, Z.: "Hofmeister effects: an explanation for the impact of ionic liquids on biocatalysis", JOURNAL OF BIOTECHNOLOGY, vol. 144, no. 1, 2009, pages 12 - 22, Retrieved from the Internet <URL:https://doi.org/10.1016/j.jbiotec.2009.04.011> |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8163526B2 (en) | Ethanol production | |
JP5805202B2 (en) | Microorganism producing O-phosphoserine and method for producing L-cysteine or a derivative thereof from O-phosphoserine using the same | |
US20060148041A1 (en) | Method for fermentative production of amino acids and amino acid derivatives of the phosphoglycerate family | |
Siedler et al. | Reductive whole-cell biotransformation with Corynebacterium glutamicum: improvement of NADPH generation from glucose by a cyclized pentose phosphate pathway using pfkA and gapA deletion mutants | |
RU2678757C2 (en) | Microorganism for methionine production with enhanced methionine efflux | |
EP2591091B1 (en) | Method for the preparation of 1,3-propanediol from sucrose | |
WO2010022763A1 (en) | Method for the preparation of 2-hydroxy-isobutyrate | |
WO2017144671A1 (en) | Improved biological processes for the production of aryl sulfates | |
WO2008101857A2 (en) | Coryneform bacteria with formate-thf-synthetase and/or glycine cleavage activity | |
JP2023512327A (en) | Modified Microorganisms and Methods for Improved Production of Ectoines | |
RU2723714C2 (en) | Method and microorganism for enzymatic production of methionine with improved output of methionine | |
CA2922597A1 (en) | Microorganism for methionine production with improved methionine synthase activity and methionine efflux | |
Zhu et al. | Combining fermentation to produce O-succinyl-l-homoserine and enzyme catalysis for the synthesis of l-methionine in one pot | |
JP5707318B2 (en) | Method for producing L-lysine | |
WO2015031504A1 (en) | RECOMBINANT PATHWAY AND ORGANISMS FOR MALONYL-CoA SYNTHESIS | |
US20100015681A1 (en) | Hydrogen Production By Means Of A Cell Expression System | |
WO2024013258A1 (en) | Production of cysteine or cystine from serine in fermentation medium | |
Schwentner et al. | Exploring the potential of Corynebacterium glutamicum to produce the compatible solute mannosylglycerate | |
JP2010183858A (en) | Gene recombination microorganism and method for producing 3-hydroxypropionic acid using the same | |
KR102028161B1 (en) | Process for preparing 2,3-butanediol using transformant | |
JP5847840B2 (en) | Fermentative production of methionine hydroxy analogue (MHA) | |
EP3470512A1 (en) | Mutant phosphoserine aminotransferase for the conversion of homoserine into 4-hydroxy-2-ketobutyrate | |
US20190352684A1 (en) | Arylalkylamine n-acetyltransferase and uses thereof | |
EP4431609A1 (en) | Method for improving 2, 4 dihydroxybutyric acid production and yield | |
KR20200046551A (en) | Recombinant Corynebacterium glutamicum strains and method of producing cadaverine using the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23741396 Country of ref document: EP Kind code of ref document: A1 |